US20160058682A1 - Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent - Google Patents

Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent Download PDF

Info

Publication number
US20160058682A1
US20160058682A1 US14/845,342 US201514845342A US2016058682A1 US 20160058682 A1 US20160058682 A1 US 20160058682A1 US 201514845342 A US201514845342 A US 201514845342A US 2016058682 A1 US2016058682 A1 US 2016058682A1
Authority
US
United States
Prior art keywords
radicals
group
compounds
denotes
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/845,342
Inventor
Herve Richard
Benoit Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1051823A external-priority patent/FR2957250B1/en
Priority claimed from FR1059756A external-priority patent/FR2967900B1/en
Application filed by LOreal SA filed Critical LOreal SA
Priority to US14/845,342 priority Critical patent/US20160058682A1/en
Publication of US20160058682A1 publication Critical patent/US20160058682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/30Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C07C309/12Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing esterified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/20Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C309/22Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/23Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the present invention relates to a cosmetic composition containing a combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • the invention also relates to a process for the radiation-photostabilization of at least one screening agent of the dibenzoylmethane derivative type with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • UV-B radiation It is known that light radiation with wavelengths of between 280 nm and 400 nm permits tanning of the human epidermis and that light rays with wavelengths more particularly between 280 and 320 nm, known as UV-B rays, cause skin burns and erythema which can harm the development of a natural tan. For these reasons, and also for aesthetic reasons, there is constant demand for means for controlling this natural tanning in order thus to control the colour of the skin; this UV-B radiation should thus be screened out.
  • UV-A rays with wavelengths between 320 and 400 nm, which cause tanning of the skin, are liable to induce adverse changes therein, in particular in the case of sensitive skin or skin that is continually exposed to solar radiation.
  • UV-A rays cause in particular a loss of elasticity of the skin and the appearance of wrinkles leading to premature ageing of the skin. They promote triggering of the erythemal reaction or amplify this reaction in certain individuals and may even be the cause of phototoxic or photoallergic reactions.
  • people increasingly wish to control the effect of UV-A rays on their skin. It is thus desirable also to screen out UV-A radiation.
  • antisun compositions comprising organic screening agents that are active in the UV-A range and in the UV-B range are generally used.
  • the majority of these screening agents are liposoluble.
  • one particularly advantageous family of UV-A screening agents currently consists of dibenzoylmethane derivatives, and in particular 4-tert-butyl-4′-methoxydibenzoylmethane, which have high intrinsic absorbing power.
  • dibenzoylmethane derivatives which are products that are now well known per se as screening agents that are active in the UV-A range, are described in particular in French patent applications FR-A-2 326 405 and FR-A-2 440 933, and also in European patent application EP-A-0 114 607; 4-tert-butyl-4′-methoxy-dibenzoylmethane is moreover currently sold under the trade name Parsol 1789® by the company DSM Nutritional Products.
  • dibenzoyl-methane derivatives are products that are relatively sensitive to ultraviolet radiation (especially UV-A), i.e., more specifically, they have an annoying tendency to be degraded more or less quickly under the action of this radiation.
  • UV-A ultraviolet radiation
  • this substantial lack of photochemical stability of dibenzoylmethane derivatives towards ultraviolet radiation, to which they are by nature intended to be subjected does not make it possible to ensure constant protection during prolonged exposure to the sun, and so the user must make repeated applications at regular and close time intervals in order to obtain effective protection of the skin against UV rays.
  • Patent application WO 01/28732 discloses a process for photostabilizing a dibenzoylmethane derivative with a merocyanin phenyl sulfone derivative. Firstly, this photostabilization of the dibenzoylmethane derivative with the merocyanin phenyl sulfone derivative is not entirely satisfactory. Secondly, these merocyanin phenyl sulfone derivatives have the drawback of being degraded in the presence of dibenzoylmethane under the influence of UV radiation.
  • Patent application WO 2008/090 066 has already proposed photostabilizing dibenzoylmethane derivatives with cyclic merocyanin cyanoacetate derivatives.
  • the photostabilization of the dibenzoylmethane derivative remains insufficient and these merocyanin cyanoacetate derivatives also have the drawback of being degraded in the presence of dibenzoylmethane.
  • the Applicant has now discovered, surprisingly, that by combining the dibenzoylmethane derivatives mentioned above with a particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given later, which are active in the UV-A range, it is possible firstly to substantially improve the photochemical stability (or photostability) of the dibenzoylmethane derivatives and, secondly, to extend the filtration of the composition in the longer UV-A range while at the same time giving cosmetically acceptable coloration.
  • composition comprising, in a cosmetically acceptable support, at least one UV-screening system, characterized in that it comprises:
  • Another subject of the invention also concerns a process for improving the chemical stability towards UV radiation of at least one dibenzoylmethane derivative, which consists in combining the said dibenzoylmethane derivative with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • cosmetically acceptable means compatible with the skin and/or its integuments, which has a pleasant colour, odour and feel, and which does not cause any unacceptable discomfort (stinging, tautness or redness) liable to dissuade the consumer from using this composition.
  • hydrophilic UV-screening agent means any agent for screening out UV radiation, which may be soluble in an aqueous phase at 1-5% by weight (transparent) or water-dispersible in the form of a suspension of particles smaller than 100 microns.
  • water-soluble screening agent means any agent for screening out UV radiation, which may be soluble in its cosmetically acceptable salt form in an aqueous phase at more than 5% by weight.
  • the term “effective amount” means an amount that is sufficient to obtain a notable and significant improvement in the photostability of the dibenzoylmethane derivative(s) in the cosmetic composition.
  • This minimum amount of merocyanin derivatives according to the invention which may vary according to the nature of the support adopted for the composition, may be determined without any difficulty by means of a standard test for measuring photostability, such as the test given in the examples hereinbelow.
  • dibenzoylmethane derivatives that may especially be mentioned, in a non-limiting manner, are:
  • 4-isopropyldibenzoylmethane will be used in particular, which is sold under the name Eusolex 8020 by the company Merck, and corresponds to the following formula:
  • the dibenzoylmethane derivative(s) may be present in the compositions in accordance with the invention in contents preferably ranging from 0.01% to 20% by weight, more preferentially from 0.1% to 10% by weight and even more preferentially from 0.1% to 6% by weight relative to the total weight of the composition.
  • hydrophilic or water-soluble merocyanin compounds in accordance with the invention are chosen from the group formed by:
  • the merocyanin compounds of the invention may be in the E,E-, E,Z- or Z,Z-geometrical isomer forms.
  • diradical means a divalent radical such that the two units
  • linear or branched alkyl radicals examples include: methyl, ethyl, n-propyl, isopropyl, 1-methylethyl, butyl, pentyl, hexyl, 2-ethylhexyl, octyl, 1-methylheptyl.
  • C 3 -C 8 cycloalkyl radicals that may be mentioned include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-methylcyclopropyl, 1-ethylcyclopropyl, 1-propylcyclopropyl, 1-butylcyclopropyl, 1-methyl-1-butylcyclopropyl, 1,2-dimethylcyclypropyl, 1-methyl-2-ethylcyclopropyl and cyclooctyl.
  • the acceptable salts of the merocyanin compounds described in the present invention comprise conventional non-toxic salts of the said compounds, such as those formed from organic or mineral bases, such as amine salts, for instance salts of alkanolamines such as triethanolamine, amino acid salts or aminopropanediol salts, and salts of an alkali metal or alkaline-earth metal, for instance sodium or potassium.
  • amine salts for instance salts of alkanolamines such as triethanolamine, amino acid salts or aminopropanediol salts, and salts of an alkali metal or alkaline-earth metal, for instance sodium or potassium.
  • the preferred salts are salts of an alkali metal such as sodium or potassium, or salts of an amine such as triethanolamine.
  • R 1 denotes hydrogen; a linear or branched C 1 -C 8 alkyl radical possibly containing from 1 to 3 oxygen atoms
  • R 2 denotes a linear or branched C 1 -C 8 alkyl radical possibly containing from 1 to 3 oxygen atoms or a C 5 -C 6 cycloalkyl radical
  • R 3 denotes a group —COOR 5 , —CN or —CONHR 5
  • R 4 denotes a group —COOR 6 , —CONHR 6 or —SO 2 R 6
  • R 5 denotes a linear or branched C 1 -C 12 alkyl radical possibly containing from 1 to 3 oxygen atoms
  • n is equal to 1 or 2; with at least one or two of the radicals R 1 , R 2 , R 5 , R 6 containing
  • R 1 denotes hydrogen; a linear or branched C 1 -C 10 alkyl radical possibly containing from 1 to 3 oxygen atoms
  • R 2 denotes a linear or branched C 1 -C 10 alkyl radical possibly containing from 1 to 3 oxygen atoms
  • R 3 denotes a group —COOR 5 or CN
  • R 4 denotes a group —COOR 6 or —SO 2 R 6
  • R 5 denotes a linear or branched C 1 -C 12 alkyl radical possibly containing from 1 to 3 oxygen atoms
  • Z is —(CH 2 ) 3 — which may or may not be substituted with two groups CH 3
  • n is equal to 1 or 2; with at least one or two of the radicals R 1 , R 2 , R 5 , R 6 containing
  • linear merocyanin derivatives in accordance with the invention in particular those of formula (I), may be prepared according to a method described in patents U.S. Pat. No. 4,045,229, U.S. Pat. No. 4,195,999 and US 2009/0 170 008 according to the following scheme (route 1):
  • cyclic merocyanin derivatives in accordance with the invention in particular those of formula (II), may be prepared according to a method described in IP.COM Journal 9(5A), 29-30 (2009) according to the following scheme:
  • hydrophilic or water-soluble merocyanin compounds in accordance with the invention are novel and constitute another subject of the invention.
  • hydrophilic or water-soluble merocyanin screening agent(s) in accordance with the invention may be present in the compositions according to the invention in a concentration of between 0.1% and 10% and preferably between 0.2% and 5% by weight relative to the total weight of the composition.
  • compositions in accordance with the invention may also comprise other additional UVA-active and/or UVB-active organic or mineral UV-screening agents that are water-soluble or liposoluble or even insoluble in the cosmetic solvents commonly used.
  • the additional organic screening agents are chosen especially from anthranilates; cinnamic derivatives; salicylic derivatives; camphor derivatives; benzophenone derivatives; ⁇ , ⁇ diphenylacrylate derivatives; triazine derivatives other than those of formula (II); benzotriazole derivatives; benzalmalonate derivatives, especially those mentioned in patent U.S. Pat. No. 5,624,663; benzimidazole derivatives; imidazolines; bis-benzazolyl derivatives as described in patents EP 669 323 and U.S. Pat. No.
  • organic UV-screening agents mention may be made of those denoted hereinbelow under their INCI name:
  • Ethylhexyl dimethyl PABA sold in particular under the name Escalol 507 by ISP, Glyceryl PABA, PEG-25 PABA sold under the name Uvinul P25 by BASF,
  • Ethylhexyl methoxycinnamate sold especially under the trade name Parsol MCX by DSM Nutritional Products, Isopropyl methoxycinnamate, Isoamyl methoxycinnamate sold under the trade name Neo Heliopan E 1000 by Symrise,
  • Benzophenone-1 sold under the trade name Uvinul 400 by BASF
  • Benzophenone-2 sold under the trade name Uvinul D50 by BASF
  • Benzophenone-3 or Oxybenzone sold under the trade name Uvinul M40 by BASF
  • Benzophenone-4 sold under the trade name Uvinul MS40 by BASF
  • Benzophenone-6 sold under the trade name Helisorb 11 by Norquay
  • Benzophenone-8 sold under the trade name Spectra-Sorb UV-24 by American Cyanamid
  • Benzophenone-9 sold under the trade name Uvinul DS-49 by BASF
  • Phenylbenzimidazolesulfonic acid sold in particular under the trade name Eusolex 232 by Merck, Disodium phenyl dibenzimidazole tetrasulfonate sold under the trade name Neo Heliopan AP by Symrise,
  • Neo Heliopan MA Menthyl anthranilate sold under the trade name Neo Heliopan MA by Symrise,
  • the preferential additional organic screening agents are chosen from:
  • the additional mineral screening agents are chosen from coated or uncoated metal oxide pigments, for instance pigments of titanium oxide (amorphous or crystallized in rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide or cerium oxide, which are all UV-photoprotective agents that are well known per se.
  • the pigments may be coated or uncoated.
  • the coated pigments are pigments that have undergone one or more surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53-64, such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminium salts of fatty acids, metal alkoxides (of titanium or of aluminium), polyethylene, silicones, proteins (collagen, elastin), alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate.
  • surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53-64 such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron
  • silicones are organosilicon polymers or oligomers of linear or cyclic, branched or crosslinked structure, of variable molecular weight, obtained by polymerization and/or polycondensation of suitably functionalized silanes, and consist essentially of a repetition of main units in which the silicon atoms are linked together via oxygen atoms (siloxane bond), optionally substituted hydrocarbon-based radicals being directly attached via a carbon atom to the said silicon atoms.
  • sicones also includes the silanes required for their preparation, in particular alkyl silanes.
  • the silicones used for coating the nanopigments that are suitable for the present invention are preferably chosen from the group containing alkyl silanes, polydialkylsiloxanes and polyalkylhydrogenosiloxanes. Even more preferentially, the silicones are chosen from the group containing octyltrimethylsilane, polydimethylsiloxanes and polymethylhydrogenosiloxanes.
  • the metal oxide pigments may have been treated with other surface agents, in particular with cerium oxide, alumina, silica, aluminium compounds or silicon compounds, or mixtures thereof.
  • coated pigments are, for example, titanium oxides that have been coated: with silica, such as the product Sunveil from the company Ikeda and the product Eusolex T-AVO from the company Merck,
  • silica and iron oxide such as the product Sunveil F from the company Ikeda
  • silica and alumina such as the products Microtitanium Dioxide MT 500 SA and Microtitanium Dioxide MT 100 SA from the company Tayca
  • Tioveil from the company Tioxide and Mirasun TiW 60 from the company Rhodia
  • alumina such as the products Tipaque TTO-55 (B) and Tipaque TTO-55 (A) from the company Ishihara and UVT 14/4 from the company Kemira
  • alumina and aluminium stearate such as the product Microtitanium Dioxide MT 100 TV, MT 100 TX, MT 100 Z and MT-01 from the company Tayca
  • silica, alumina and alginic acid such as the product MT-100 AQ from the company Tay
  • titanium oxide pigments treated with a silicone are, for example, TiO 2 treated with octyltrimethylsilane, such as the product sold under the trade name T 805 by the company Degussa Silicas, TiO 2 treated with a polydimethylsiloxane, such as the product sold under the trade name 70250 Cardre UF TiO2SI3 by the company Cardre, anatase/rutile TiO 2 treated with a polydimethylhydrogenosiloxane, such as the product sold under the trade name Microtitanium Dioxide USP Grade Hydrophobic by the company Color Techniques.
  • TiO 2 treated with octyltrimethylsilane such as the product sold under the trade name T 805 by the company Degussa Silicas
  • TiO 2 treated with a polydimethylsiloxane such as the product sold under the trade name 70250 Cardre UF TiO2SI3 by the company Cardre
  • the uncoated titanium oxide pigments are sold, for example, by the company Tayca under the trade names Microtitanium Dioxide MT 500 B or Microtitanium Dioxide MT 600 B, by the company Degussa under the name P 25, by the company Wacker under the name Transparent titanium oxide PW, by the company Miyoshi Kasei under the name UFTR, by the company Tomen under the name ITS and by the company Tioxide under the name Tioveil AQ.
  • the uncoated zinc oxide pigments are, for example:
  • coated zinc oxide pigments are, for example:
  • the uncoated cerium oxide pigments are sold, for example, under the name Colloidal Cerium Oxide by the company Rhône-Poulenc.
  • the uncoated iron oxide nanopigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2002 (FE 45B), Nanogard Iron FE 45 BL AQ, Nanogard FE 45R AQ and Nanogard WCD 2006 (FE 45R) or by the company Mitsubishi under the name TY-220,
  • the coated iron oxide pigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2008 (FE 45B FN), Nanogard WCD 2009 (FE 45B 556), Nanogard FE 45 BL 345 and Nanogard FE 45 BL or by the company BASF under the name Transparent Iron Oxide.
  • the additional UV-screening agents are generally present in the compositions according to the invention in proportions ranging from 0.01% to 20% by weight relative to the total weight of the composition, and preferably ranging from 0.1% to 10% by weight relative to the total weight of the composition.
  • compositions in accordance with the present invention may also comprise standard cosmetic adjuvants chosen especially from oils, waxes, organic solvents, ionic or nonionic, hydrophilic or lipophilic thickeners, softeners, humectants, opacifiers, stabilizers, emollients, silicones, antifoams, fragrances, preserving agents, anionic, cationic, nonionic, zwitterionic or amphoteric surfactants, active agents, fillers, polymers, propellants, acidifying or basifying agents or any other ingredient usually used in cosmetics and/or dermatology.
  • standard cosmetic adjuvants chosen especially from oils, waxes, organic solvents, ionic or nonionic, hydrophilic or lipophilic thickeners, softeners, humectants, opacifiers, stabilizers, emollients, silicones, antifoams, fragrances, preserving agents, anionic, cationic, nonionic, zwitterionic or
  • Oils that may be mentioned include mineral oils (paraffin); plant oils (sweet almond oil, macadamia oil, blackcurrant seed oil or jojoba oil); synthetic oils, for instance perhydrosqualene, fatty alcohols, fatty amides (for instance isopropyl lauroyl sarcosinate sold under the name Eldew SL-205 by the company Ajinomoto), fatty acids or fatty esters, for instance the C12-C15 alkyl benzoate sold under the trade name Finsolv TN or Witconol TN by the company Witco, 2-ethylphenyl benzoate, for instance the commercial product sold under the name X-Tend 226® by the company ISP, octyl palmitate, isopropyl lanolate and triglycerides, including capric/caprylic acid triglycerides, and dicaprylyl carbonate sold under the name Cetiol CC by the company Cognis, oxyethyl
  • waxy compounds examples include carnauba wax, beeswax, hydrogenated castor oil, polyethylene waxes and polymethylene waxes, for instance the product sold under the name Cirebelle 303 by the company Sasol.
  • organic solvents that may be mentioned are lower alcohols and polyols.
  • These polyols may be chosen from glycols and glycol ethers, for instance ethylene glycol, propylene glycol, butylene glycol, dipropylene glycol or diethylene glycol.
  • Hydrophilic thickeners that may be mentioned include carboxyvinyl polymers, such as Carbopols (Carbomers) and the Pemulens (acrylate/C10-C30-alkyl acrylate copolymer); polyacrylamides, for instance the crosslinked copolymers sold under the names Sepigel 305 (CTFA name: polyacrylamide/C13-14 isoparaffin/Laureth 7) or Simulgel 600 (CTFA name: acrylamide/sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80) by the company SEPPIC; 2-acrylamido-2-methylpropanesulfonic acid polymers and copolymers, optionally crosslinked and/or neutralized, for instance poly(2-acrylamido-2-methylpropanesulfonic acid) sold by the company Hoechst under the trade name Hostacerin AMPS (CTFA name: ammonium polyacryloyldimethyl taurate or Simulgel 800 sold
  • Lipophilic thickeners that may be mentioned include synthetic polymers, such as the poly(C10-C30 alkyl acrylates) sold under the names Intelimer IPA 13-1 and Intelimer IPA 13-6 by Landec, or modified clays, such as hectorite and its derivatives, for instance the products sold under the name Bentone.
  • compositions according to the invention may be prepared according to the techniques that are well known to those skilled in the art. They may in particular be in the form of a simple or complex emulsion (O/W, W/O, O/W/O or W/O/W) such as a cream, a milk or a cream-gel; in the form of an aqueous gel; in the form of a lotion. They may optionally be packaged as an aerosol and may be in the form of a mousse or a spray.
  • compositions according to the invention are preferably in the form of an oil-in-water or water-in-oil emulsion.
  • the emulsification processes that may be used are of paddle or impeller, rotor-stator and high-pressure homogenizer (HPH) type.
  • the emulsions generally contain at least one emulsifying surfactant chosen from amphoteric, anionic, cationic and nonionic emulsifying surfactants, which are used alone or as a mixture.
  • the emulsifiers are appropriately chosen according to the emulsion to be obtained (W/O or O/W).
  • emulsifying surfactants that may be used for the preparation of the W/O emulsions
  • examples that may be mentioned include sorbitan, glycerol or sugar alkyl esters or ethers; silicone surfactants, for instance dimethicone copolyols, such as the mixture of cyclomethicone and of dimethicone copolyol, sold under the name DC 5225 C by the company Dow Corning, and alkyldimethicone copolyols such as laurylmethicone copolyol sold under the name Dow Corning 5200 Formulation Aid by the company Dow Corning; cetyl-dimethicone copolyol, such as the product sold under the name Abil EM 90R by the company Goldschmidt, and the mixture of cetyldimethicone copolyol, of polyglyceryl isostearate (4 mol) and of hexyl laurate, sold under the name Abil WE O9 by the company Gold
  • Polyol alkyl esters that may especially be mentioned include polyethylene glycol esters, for instance PEG-30 dipolyhydroxystearate, such as the product sold under the name Arlacel P135 by the company ICI.
  • Glycerol and/or sorbitan esters that may especially be mentioned include, for example, polyglyceryl isostearate, such as the product sold under the name Isolan GI 34 by the company Goldschmidt, sorbitan isostearate, such as the product sold under the name Arlacel 987 by the company ICI, sorbitan glyceryl isostearate, such as the product sold under the name Arlacel 986 by the company ICI, and mixtures thereof.
  • emulsifiers examples include nonionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) fatty acid esters of glycerol; oxyalkylenated fatty acid esters of sorbitan; oxyalkyl-enated (oxyethylenated and/or oxypropylenated) fatty acid esters, for instance the mixture PEG-100 stearate/glyceryl stearate sold, for example, by the company ICI under the name Arlacel 165; oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alkyl ethers; sugar esters, for instance sucrose stearate; fatty alkyl ethers of sugars, especially polyalkylglucosides (APG) such as decylglucoside and laurylglucoside sold, for example, by the company He
  • APG polyalkylglucosides
  • the mixture of the alkyl polyglucoside as defined above with the corresponding fatty alcohol can be in the form of a self-emulsifying composition, for example as disclosed in the document WO-A-92/06778.
  • the aqueous phase of this emulsion may comprise a nonionic vesicular dispersion prepared according to known processes (Bangham, Standish and Watkins, J. Mol. Biol. 13, 238 (1965), FR 2 315 991 and FR 2 416 008).
  • compositions according to the invention find their application in a large number of treatments, especially cosmetic treatments, of the skin, the lips and the hair, including the scalp, especially for protecting and/or caring for the skin, the lips and/or the hair, and/or for making up the skin and/or the lips.
  • compositions according to the invention as defined above for the manufacture of cosmetic products for treating the skin, the lips, the nails, the hair, the eyelashes, the eyebrows and/or the scalp, especially care products, antisun products and makeup products.
  • the cosmetic compositions according to the invention may be used, for example, as makeup products.
  • compositions according to the invention may be used, for example, as care products and/or antisun protection products for the face and/or the body, of liquid to semi-liquid consistency, such as milks, more or less rich creams, cream-gels and pastes. They may optionally be packaged as an aerosol and may be in the form of a mousse or a spray.
  • compositions according to the invention in the form of vaporizable fluid lotions in accordance with the invention are applied to the skin or the hair in the form of fine particles by means of pressurization devices.
  • the devices in accordance with the invention are well known to those skilled in the art and comprise non-aerosol pumps or “atomizers”, aerosol containers comprising a propellant and also aerosol pumps using compressed air as propellant. These devices are described in patents U.S. Pat. No. 4,077,441 and U.S. Pat. No. 4,850,517 (which form an integral part of the content of the description).
  • compositions conditioned in aerosol form in accordance with the invention generally contain conventional propellants, for instance hydrofluoro compounds, dichlorodifluoromethane, difluoroethane, dimethyl ether, isobutane, n-butane, propane or trichlorofluoromethane. They are preferably present in amounts ranging from 15% to 50% by weight relative to the total weight of the composition.
  • compositions according to the invention may also comprise additional cosmetic or dermatological active agents.
  • a person skilled in the art will select the said active agent(s) as a function of the effect desired on the skin, the hair, the eyelashes, the eyebrows and the nails.
  • composition may also comprise at least one ingredient such as fillers with a soft-focus effect or agents for promoting the natural coloration of the skin, intended for complementing the biological effects of these active agents or for providing an immediate visual anti-ageing effect.
  • ingredient such as fillers with a soft-focus effect or agents for promoting the natural coloration of the skin, intended for complementing the biological effects of these active agents or for providing an immediate visual anti-ageing effect.
  • composition may also comprise at least one additional ingredient intended to provide an immediate visual effect. Mention may be made especially of agents that promotes the naturally pinkish coloration of the skin.
  • agents that promote the naturally pinkish coloration of the skin examples that may be mentioned include self-tanning agents, for instance an agent which, when applied to the skin, especially to the face, makes it possible to obtain a tanning effect more or less similar in appearance to that which may result from prolonged exposure to sunlight (natural tanning) or under a UV lamp.
  • self-tanning agents examples include:
  • DHA dihydroxyacetone
  • erythrulose erythrulose
  • a catalytic system formed from: manganese and/or zinc oxide salts, and alkali metal and/or alkaline-earth metal hydrogen carbonates.
  • the self-tanning agents are generally chosen from monocarbonyl or polycarbonyl compounds, for instance isatin, alloxan, ninhydrin, glyceraldehyde, mesotartaric aldehyde, glutaraldehyde, erythrulose, pyrazoline-4,5-dione derivatives as described in patent application FR 2 466 492 and WO 97/35842, dihydroxyacetone (DHA) and 4,4-dihydroxypyrazolin-5-one derivatives as described in patent application EP 903 342. DHA will preferably be used.
  • isatin isatin, alloxan, ninhydrin, glyceraldehyde, mesotartaric aldehyde, glutaraldehyde, erythrulose, pyrazoline-4,5-dione derivatives as described in patent application FR 2 466 492 and WO 97/35842, dihydroxyacetone (DHA) and 4,4-d
  • the DHA may be used in free and/or encapsulated form, for example in lipid vesicles such as liposomes, especially described in patent application WO 97/25970.
  • the self-tanning agent is present in an amount ranging from 0.01% to 20% by weight and preferably in an amount of between 0.1% and 10% of the total weight of the composition.
  • These dyes may be chosen from synthetic or natural direct dyes.
  • dyes may be chosen, for example, from red or orange dyes of the fluorane type such as those described in patent application FR 2 840 806. Mention may be made, for example, of the following dyes:
  • These dyes may also be chosen from anthraquinones, caramel, carmine, carbon black, azulene blues, methoxalene, trioxalene, guajazulene, chamuzulene, rose Bengal, eosin 10B, cyanosin and daphinin.
  • dyes may also be chosen from indole derivatives, for instance the monohydroxyindoles as described in patent FR 2 651 126 (i.e.: 4-, 5-, 6- or 7-hydroxyindole) or the dihydroxyindoles as described in patent EP-B-0 425 324 (i.e.: 5,6-dihydroxyindole, 2-methyl-5,6-dihydroxyindole, 3-methyl-5,6-dihydroxyindole or 2,3-dimethyl-5,6-dihydroxyindole).
  • indole derivatives for instance the monohydroxyindoles as described in patent FR 2 651 126 (i.e.: 4-, 5-, 6- or 7-hydroxyindole) or the dihydroxyindoles as described in patent EP-B-0 425 324 (i.e.: 5,6-dihydroxyindole, 2-methyl-5,6-dihydroxyindole, 3-methyl-5,6-dihydroxyindole or 2,3
  • 3-Anilinoacrolein aniline (2 g, 9 ⁇ 10 ⁇ 3 mol) and methylmethanesulfonyl acetate (1.37 ml, 9 ⁇ 10 ⁇ 3 mol) are heated at 105° C. in 5 ml of acetic anhydride for 2 hours 30 minutes. After cooling, the acetic anhydride is evaporated off under vacuum. The brown solid obtained is taken up in 40 ml of methanol and brought to reflux. After cooling, the solid obtained is filtered off, rinsed with cold methanol and dried.
  • Thionyl chloride (15 ml) is reacted, with stirring, with cyanoacetic acid (2 g, 0.024 mol) and maintained at 40° C. for 2 hours. 50 ml of toluene are added and the mixture is concentrated under vacuum until a residual volume of 10 ml is obtained. The sodium salt of isethionic acid (3.48 g, 0.024 mol) is added thereto and the mixture is maintained at the reflux point of the toluene. The heterogeneous mixture is refluxed for 20 hours. After cooling, the reaction mixture is filtered. The solid is taken up in water and the aqueous phase is washed with ethyl acetate. The aqueous phase is brought to neutral pH with 2N sodium hydroxide.
  • compositions A and B were Prepared

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a cosmetic composition containing a combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, especially corresponding to one of the formulae (I) or (II) below:
Figure US20160058682A1-20160303-C00001
in which at least one or two of the radicals contain:
    • either an alkylsulfonate radical in its acid or salified form
    • or one or two hydroxyl radicals. The invention also relates to a process for the radiation-photostabilization of at least one screening agent of the dibenzoylmethane derivative type with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, especially corresponding to one of the formulae (I) or (II).

Description

  • This application is a Divisional of U.S. patent application Ser. No. 13/634,194 filed on Nov. 16, 2012, which is a National Phase filing under 35 U.S.C. §371 of PCT/EP2011/053376 filed on Mar. 7, 2011; and this application claims priority to Application No. 1051823 filed in France on Mar. 15, 2010 under 35 U.S.C. §119, and this application claims priority to Application No. 1058690 filed in Oct. 22, 2010 on France under 35 U.S.C. §119, and this application claims priority to Application No. 1059756 filed in France on Nov. 25, 2010 under 35 U.S.C. §119; and this application claims the benefit of U.S. Provisional Application No. 61/282,733 filed on Mar. 24, 2010; the entire contents of each application is hereby incorporated by reference.
  • The present invention relates to a cosmetic composition containing a combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • The invention also relates to a process for the radiation-photostabilization of at least one screening agent of the dibenzoylmethane derivative type with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • It is known that light radiation with wavelengths of between 280 nm and 400 nm permits tanning of the human epidermis and that light rays with wavelengths more particularly between 280 and 320 nm, known as UV-B rays, cause skin burns and erythema which can harm the development of a natural tan. For these reasons, and also for aesthetic reasons, there is constant demand for means for controlling this natural tanning in order thus to control the colour of the skin; this UV-B radiation should thus be screened out.
  • It is also known that UV-A rays, with wavelengths between 320 and 400 nm, which cause tanning of the skin, are liable to induce adverse changes therein, in particular in the case of sensitive skin or skin that is continually exposed to solar radiation. UV-A rays cause in particular a loss of elasticity of the skin and the appearance of wrinkles leading to premature ageing of the skin. They promote triggering of the erythemal reaction or amplify this reaction in certain individuals and may even be the cause of phototoxic or photoallergic reactions. Thus, for aesthetic and cosmetic reasons, for instance conservation of the skin's natural elasticity, people increasingly wish to control the effect of UV-A rays on their skin. It is thus desirable also to screen out UV-A radiation.
  • For the purpose of protecting the skin and keratin materials against UV radiation, antisun compositions comprising organic screening agents that are active in the UV-A range and in the UV-B range are generally used. The majority of these screening agents are liposoluble.
  • In this respect, one particularly advantageous family of UV-A screening agents currently consists of dibenzoylmethane derivatives, and in particular 4-tert-butyl-4′-methoxydibenzoylmethane, which have high intrinsic absorbing power. These dibenzoylmethane derivatives, which are products that are now well known per se as screening agents that are active in the UV-A range, are described in particular in French patent applications FR-A-2 326 405 and FR-A-2 440 933, and also in European patent application EP-A-0 114 607; 4-tert-butyl-4′-methoxy-dibenzoylmethane is moreover currently sold under the trade name Parsol 1789® by the company DSM Nutritional Products.
  • Unfortunately, it has been found that dibenzoyl-methane derivatives are products that are relatively sensitive to ultraviolet radiation (especially UV-A), i.e., more specifically, they have an annoying tendency to be degraded more or less quickly under the action of this radiation. Thus, this substantial lack of photochemical stability of dibenzoylmethane derivatives towards ultraviolet radiation, to which they are by nature intended to be subjected, does not make it possible to ensure constant protection during prolonged exposure to the sun, and so the user must make repeated applications at regular and close time intervals in order to obtain effective protection of the skin against UV rays.
  • Patent application WO 01/28732 discloses a process for photostabilizing a dibenzoylmethane derivative with a merocyanin phenyl sulfone derivative. Firstly, this photostabilization of the dibenzoylmethane derivative with the merocyanin phenyl sulfone derivative is not entirely satisfactory. Secondly, these merocyanin phenyl sulfone derivatives have the drawback of being degraded in the presence of dibenzoylmethane under the influence of UV radiation.
  • Patent application WO 2008/090 066 has already proposed photostabilizing dibenzoylmethane derivatives with cyclic merocyanin cyanoacetate derivatives. In this case also, the photostabilization of the dibenzoylmethane derivative remains insufficient and these merocyanin cyanoacetate derivatives also have the drawback of being degraded in the presence of dibenzoylmethane.
  • The photostabilization of dibenzoylmethane derivatives towards UV radiation thus constitutes, at the present time, a problem that has still not been solved entirely satisfactorily.
  • The Applicant has now discovered, surprisingly, that by combining the dibenzoylmethane derivatives mentioned above with a particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given later, which are active in the UV-A range, it is possible firstly to substantially improve the photochemical stability (or photostability) of the dibenzoylmethane derivatives and, secondly, to extend the filtration of the composition in the longer UV-A range while at the same time giving cosmetically acceptable coloration.
  • This discovery forms the basis of the present invention.
  • Thus, in accordance with one of the subjects of the present invention, a composition is now proposed comprising, in a cosmetically acceptable support, at least one UV-screening system, characterized in that it comprises:
  • (i) at least one dibenzoylmethane derivative and
    (ii) at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • Another subject of the invention also concerns a process for improving the chemical stability towards UV radiation of at least one dibenzoylmethane derivative, which consists in combining the said dibenzoylmethane derivative with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, the definition of which will be given below.
  • Other characteristics, aspects and advantages of the invention will emerge on reading the detailed description that follows.
  • The term “cosmetically acceptable” means compatible with the skin and/or its integuments, which has a pleasant colour, odour and feel, and which does not cause any unacceptable discomfort (stinging, tautness or redness) liable to dissuade the consumer from using this composition.
  • In the rest of the present description, the term “hydrophilic UV-screening agent” means any agent for screening out UV radiation, which may be soluble in an aqueous phase at 1-5% by weight (transparent) or water-dispersible in the form of a suspension of particles smaller than 100 microns.
  • Also, the term “water-soluble screening agent” means any agent for screening out UV radiation, which may be soluble in its cosmetically acceptable salt form in an aqueous phase at more than 5% by weight.
  • The term “effective amount” means an amount that is sufficient to obtain a notable and significant improvement in the photostability of the dibenzoylmethane derivative(s) in the cosmetic composition. This minimum amount of merocyanin derivatives according to the invention, which may vary according to the nature of the support adopted for the composition, may be determined without any difficulty by means of a standard test for measuring photostability, such as the test given in the examples hereinbelow.
  • Among the dibenzoylmethane derivatives that may especially be mentioned, in a non-limiting manner, are:
    • 2-methyldibenzoylmethane,
    • 4-methyldibenzoylmethane,
    • 4-isopropyldibenzoylmethane,
    • 4-tert-butyldibenzoylmethane,
    • 2,4-dimethyldibenzoylmethane,
    • 2,5-dimethyldibenzoylmethane,
    • 4,4′-diisopropyldibenzoylmethane,
    • 4,4′-dimethoxydibenzoylmethane,
    • 4-tert-butyl-4′-methoxydibenzoylmethane,
    • 2-methyl-5-isopropyl-4′-methoxydibenzoylmethane,
    • 2-methyl-5-tert-butyl-4′-methoxydibenzoylmethane,
    • 2,4-dimethyl-4′-methoxydibenzoylmethane,
    • 2,6-dimethyl-4-tert-butyl-4′-methoxydibenzoylmethane.
  • Among the dibenzoylmethane derivatives mentioned above, 4-isopropyldibenzoylmethane will be used in particular, which is sold under the name Eusolex 8020 by the company Merck, and corresponds to the following formula:
  • Figure US20160058682A1-20160303-C00002
  • It is most particularly preferred to use 4-(tert-butyl)-4′-methoxydibenzoylmethane or Butyl Methoxy Dibenzoylmethane or Avobenzone, sold under the trade name Parsol 1789 by the company DSM Nutritional Products, Inc.; this screening agent corresponds to the following formula:
  • Figure US20160058682A1-20160303-C00003
  • The dibenzoylmethane derivative(s) may be present in the compositions in accordance with the invention in contents preferably ranging from 0.01% to 20% by weight, more preferentially from 0.1% to 10% by weight and even more preferentially from 0.1% to 6% by weight relative to the total weight of the composition.
  • The hydrophilic or water-soluble merocyanin compounds in accordance with the invention are chosen from the group formed by:
  • (1) those corresponding to one of the formulae (I) and (II) below, and the salts thereof:
  • Figure US20160058682A1-20160303-C00004
  • in which:
      • R1 and R2, which may be identical or different, represent H; a linear or branched C1-C22 alkyl radical possibly containing from 1 to 3 oxygen atoms; a C3-C8 cycloalkyl radical, which is unsubstituted or substituted with C1-C4 alkyl radicals; the said radicals R1 and R2 possibly containing an alkylsulfonate radical in its acid or salified form or one or two hydroxyl radicals;
      • R1 and R2 may form, together with the nitrogen, a ring containing the group —(CH2)m—, which is uninterrupted or interrupted with one or more —O—, —S— or —NH—,
      • R1 may form, with the carbon alpha to the nitrogen, a ring containing the group —(CH2)m—, which is uninterrupted or interrupted with one or more —O—, —S— or —NH—,
      • R3 represents a carboxyl, —COOR5, —CONHR5, —COR5, —CONR5R1, SO2R5, or —CN group,
      • R4 represents a carboxyl, —COOR6, —CONHR6, —COR6, —CONR6R2 or SO2R6 group,
      • R5 and R6, which may be identical or different, represent a linear or branched C1-C22 alkyl radical possibly containing from 1 to 3 oxygen atoms; a C3-C8 cycloalkyl radical, which is unsubstituted or substituted with C1-C4 alkyl radicals; the said radicals R5 and R6 possibly containing an alkylsulfonate radical in its acid or salified form or one or two hydroxyl radicals,
      • Z represents the group —(CH2)l—, which is uninterrupted or interrupted with —O—, —S— or —NR7—, and/or unsubstituted or substituted with one or two C1-C6 alkyl radicals,
      • R7 is a C1-C5 alkyl radical possibly containing an alkylsulfonate radical in its acid or salified form or one or two hydroxyl radicals,
      • n is 1-2; —m is 1-7; —l is 1-4;
  • with at least one or two of the radicals R1, R2, R5, R6 and R7 containing
      • either an alkylsulfonate radical in its acid or salified form
      • or one or two hydroxyl radicals;
  • with the proviso that:
  • (i) when n=2, one of the radicals R1, R5 or R6 is an alkyl diradical or R1 and R2 together with two nitrogen atoms form a cyclic divalent radical —(CH2)m—;
    (ii) R1 and R2 are not simultaneously a hydrogen atom;
    (iii) when R3 is —CN, then at least one of the radicals R1, R2 or R6 must contain an alkylsulfonate group in its acid or salified form;
    (2) the merocyanin compounds chosen from the group formed by the following molecules, and also salts thereof and the E,E-, E,Z- or Z,Z-geometrical isomer forms thereof
  • Figure US20160058682A1-20160303-C00005
    Figure US20160058682A1-20160303-C00006
    Figure US20160058682A1-20160303-C00007
    Figure US20160058682A1-20160303-C00008
  • The merocyanin compounds of the invention may be in the E,E-, E,Z- or Z,Z-geometrical isomer forms.
  • The term “diradical” means a divalent radical such that the two units
  • Figure US20160058682A1-20160303-C00009
  • are linked together via this diradical.
  • Illustrations that may be mentioned include compounds (u) and (ar) below:
  • Figure US20160058682A1-20160303-C00010
  • In the case where n=2, for instance a cyclic divalent radical —(CH2)m— formed by R1 and R2 with the two nitrogen atoms, mention may be made of the compound (ax)
  • Figure US20160058682A1-20160303-C00011
  • Examples of linear or branched alkyl radicals that may be mentioned include: methyl, ethyl, n-propyl, isopropyl, 1-methylethyl, butyl, pentyl, hexyl, 2-ethylhexyl, octyl, 1-methylheptyl.
  • C3-C8 cycloalkyl radicals that may be mentioned include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-methylcyclopropyl, 1-ethylcyclopropyl, 1-propylcyclopropyl, 1-butylcyclopropyl, 1-methyl-1-butylcyclopropyl, 1,2-dimethylcyclypropyl, 1-methyl-2-ethylcyclopropyl and cyclooctyl.
  • The acceptable salts of the merocyanin compounds described in the present invention comprise conventional non-toxic salts of the said compounds, such as those formed from organic or mineral bases, such as amine salts, for instance salts of alkanolamines such as triethanolamine, amino acid salts or aminopropanediol salts, and salts of an alkali metal or alkaline-earth metal, for instance sodium or potassium.
  • The preferred salts are salts of an alkali metal such as sodium or potassium, or salts of an amine such as triethanolamine.
  • The preferred compounds of formula (I) are those for which the following conditions are satisfied:
  • R1 denotes hydrogen; a linear or branched C1-C8 alkyl radical possibly containing from 1 to 3 oxygen atoms,
    R2 denotes a linear or branched C1-C8 alkyl radical possibly containing from 1 to 3 oxygen atoms or a C5-C6 cycloalkyl radical,
    R3 denotes a group —COOR5, —CN or —CONHR5,
    R4 denotes a group —COOR6, —CONHR6 or —SO2R6,
    R5 denotes a linear or branched C1-C12 alkyl radical possibly containing from 1 to 3 oxygen atoms,
    n is equal to 1 or 2;
    with at least one or two of the radicals R1, R2, R5, R6 containing
      • either an alkylsulfonate radical in its acid or salified form
      • or one or two hydroxyl radicals.
  • The compounds of formula (I) with one or two alkylsulfonate radicals that are even more particularly preferred are chosen from those having the following formulae:
  • Figure US20160058682A1-20160303-C00012
    Figure US20160058682A1-20160303-C00013
  • The compounds of formula (I) containing hydroxyl groups that are particularly preferred are those having the following formulae:
  • Figure US20160058682A1-20160303-C00014
  • The preferred compounds of formula (II) are those for which the following conditions are satisfied:
  • R1 denotes hydrogen; a linear or branched C1-C10 alkyl radical possibly containing from 1 to 3 oxygen atoms,
    R2 denotes a linear or branched C1-C10 alkyl radical possibly containing from 1 to 3 oxygen atoms; a C5-C6 cycloalkyl,
    R3 denotes a group —COOR5 or CN,
    R4 denotes a group —COOR6 or —SO2R6,
    R5 denotes a linear or branched C1-C12 alkyl radical possibly containing from 1 to 3 oxygen atoms,
    Z is —(CH2)3— which may or may not be substituted with two groups CH3,
    n is equal to 1 or 2;
    with at least one or two of the radicals R1, R2, R5, R6 containing
      • either an alkylsulfonate radical in its acid or salified form
      • or one or two hydroxyl radicals.
  • The compounds of formula (II) that are particularly preferred are those having the following formulae:
  • Figure US20160058682A1-20160303-C00015
  • Among the merocyanin compounds in accordance with the invention that are particularly preferred, the following compounds will be chosen more particularly:
  • Figure US20160058682A1-20160303-C00016
    Figure US20160058682A1-20160303-C00017
  • The linear merocyanin derivatives in accordance with the invention, in particular those of formula (I), may be prepared according to a method described in patents U.S. Pat. No. 4,045,229, U.S. Pat. No. 4,195,999 and US 2009/0 170 008 according to the following scheme (route 1):
  • Figure US20160058682A1-20160303-C00018
  • or according to a method described in patent WO 00/07989, and according to the following scheme (route 2):
  • Figure US20160058682A1-20160303-C00019
  • in which the radicals R1, R2, R3 and R4 have the meaning of formula (I).
  • The cyclic merocyanin derivatives in accordance with the invention, in particular those of formula (II), may be prepared according to a method described in IP.COM Journal 9(5A), 29-30 (2009) according to the following scheme:
  • Figure US20160058682A1-20160303-C00020
      • in which the radicals R1, R2, R3, R4 and Z have the meaning of formula (II).
  • Some of the hydrophilic or water-soluble merocyanin compounds in accordance with the invention are novel and constitute another subject of the invention.
  • Among the compounds of formula (I) with one or two alkylsulfonate radicals, the following compounds are novel:
  • Figure US20160058682A1-20160303-C00021
    Figure US20160058682A1-20160303-C00022
  • Among the compounds of formula (I) containing hydroxyl groups, the following compounds are novel:
  • Figure US20160058682A1-20160303-C00023
  • The compounds of formula (II) are novel, in particular the following compounds:
  • Figure US20160058682A1-20160303-C00024
  • The following compounds are also novel:
  • Figure US20160058682A1-20160303-C00025
    Figure US20160058682A1-20160303-C00026
    Figure US20160058682A1-20160303-C00027
    Figure US20160058682A1-20160303-C00028
  • The hydrophilic or water-soluble merocyanin screening agent(s) in accordance with the invention may be present in the compositions according to the invention in a concentration of between 0.1% and 10% and preferably between 0.2% and 5% by weight relative to the total weight of the composition.
  • The compositions in accordance with the invention may also comprise other additional UVA-active and/or UVB-active organic or mineral UV-screening agents that are water-soluble or liposoluble or even insoluble in the cosmetic solvents commonly used.
  • Needless to say, a person skilled in the art will take care to select the optional additional screening agent(s) and/or the amounts thereof such that the advantageous properties intrinsically associated with the compositions in accordance with the invention are not, or are not substantially, adversely affected by the envisaged addition(s), especially the improvement in the photostability of the dibenzoylmethane derivative.
  • The additional organic screening agents are chosen especially from anthranilates; cinnamic derivatives; salicylic derivatives; camphor derivatives; benzophenone derivatives; β,βdiphenylacrylate derivatives; triazine derivatives other than those of formula (II); benzotriazole derivatives; benzalmalonate derivatives, especially those mentioned in patent U.S. Pat. No. 5,624,663; benzimidazole derivatives; imidazolines; bis-benzazolyl derivatives as described in patents EP 669 323 and U.S. Pat. No. 2,463,264; p-aminobenzoic acid (PABA) derivatives; methylenebis(hydroxyphenylbenzotriazole) derivatives as described in patent applications U.S. Pat. No. 5,237,071, U.S. Pat. No. 5,166,355, GB 2 303 549, DE 197 26 184 and EP 893 119; benzoxazole derivatives as described in patent applications EP 0 832 642, EP 1 027 883, EP 1 300 137 and DE 101 62 844; screening polymers and screening silicones such as those described especially in patent application WO 93/04665; αalkylstyrene-based dimers, such as those described in patent application DE 198 55 649; 4,4-diarylbutadienes such as those described in patent applications EP 0 967 200, DE 197 46 654, DE 197 55 649, EP-A-1 008 586, EP 1 133 980 and EP 133 981; merocyanin derivatives other than those of formula (I), such as those described in patent applications WO 04/006 878, WO 05/058 269 and WO 06/032 741; and mixtures thereof.
  • As examples of organic UV-screening agents, mention may be made of those denoted hereinbelow under their INCI name:
  • para-aminobenzoic acid derivatives:
  • PABA, Ethyl PABA, Ethyl Dihydroxypropyl PABA,
  • Ethylhexyl dimethyl PABA sold in particular under the name Escalol 507 by ISP, Glyceryl PABA,
    PEG-25 PABA sold under the name Uvinul P25 by BASF,
  • Salicylic Derivatives:
  • Homosalate sold under the name Eusolex HMS by Rona/EM Industries,
    Ethylhexyl salicylate sold under the name Neo Heliopan OS by Symrise,
    Dipropylene glycol salicylate sold under the name Dipsal by Scher,
    TEA salicylate sold under the name Neo Heliopan TS by Symrise,
  • Cinnamic Derivatives:
  • Ethylhexyl methoxycinnamate sold especially under the trade name Parsol MCX by DSM Nutritional Products,
    Isopropyl methoxycinnamate,
    Isoamyl methoxycinnamate sold under the trade name Neo Heliopan E 1000 by Symrise,
  • Cinoxate, DEA Methoxycinnamate,
  • Diisopropyl methylcinnamate,
    Glyceryl ethylhexanoate dimethoxycinnamate,
  • β,β-Diphenylacrylate Derivatives:
  • Octocrylene sold especially under the trade name Uvinul N539 by BASF,
    Etocrylene sold especially under the trade name Uvinul N35 by BASF,
  • Benzophenone Derivatives:
  • Benzophenone-1 sold under the trade name Uvinul 400 by BASF,
    Benzophenone-2 sold under the trade name Uvinul D50 by BASF,
    Benzophenone-3 or Oxybenzone sold under the trade name Uvinul M40 by BASF,
    Benzophenone-4 sold under the trade name Uvinul MS40 by BASF,
  • Benzophenone-5,
  • Benzophenone-6 sold under the trade name Helisorb 11 by Norquay,
    Benzophenone-8 sold under the trade name Spectra-Sorb UV-24 by American Cyanamid,
    Benzophenone-9 sold under the trade name Uvinul DS-49 by BASF,
  • Benzophenone-12,
  • n-hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate sold under the trade name Uvinul A+ or in the form of a mixture with octyl methoxycinnamate under the trade name Uvinul A+B by BASF,
    1,1′-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]methanone (CAS 919803-06-8),
  • Benzylidenecamphor Derivatives:
  • 3-Benzylidenecamphor manufactured under the name Mexoryl SD by Chimex,
    4-Methylbenzylidenecamphor sold under the name Eusolex 6300 by Merck,
    Benzylidenecamphorsulfonic acid manufactured under the name Mexoryl SL by Chimex,
    Camphor benzalkonium methosulfate manufactured under the name Mexoryl SO by Chimex,
    Terephthalylidenedicamphorsulfonic acid manufactured under the name Mexoryl SX by Chimex,
    Polyacrylamidomethylbenzylidenecamphor manufactured under the name Mexoryl SW by Chimex,
  • Phenylbenzimidazole Derivatives:
  • Phenylbenzimidazolesulfonic acid sold in particular under the trade name Eusolex 232 by Merck,
    Disodium phenyl dibenzimidazole tetrasulfonate sold under the trade name Neo Heliopan AP by Symrise,
  • Phenylbenzotriazole Derivatives:
  • Drometrizole trisiloxane sold under the name Silatrizole by Rhodia Chimie,
    Methylenebis(benzotriazolyl)tetramethylbutylphenol sold in solid form under the trade name Mixxim BB/100 by Fairmount Chemical, or in micronized form as an aqueous dispersion under the trade name Tinosorb M by Ciba Specialty Chemicals,
  • Triazine Derivatives:
  • Bis(ethylhexyloxyphenol)methoxyphenyltriazine sold under the trade name Tinosorb S by Ciba Geigy,
    Ethylhexyltriazone sold in particular under the trade name Uvinul T150 by BASF,
    Diethylhexylbutamidotriazone sold under the trade name Uvasorb HEB by Sigma 3V,
    2,4,6-Tris(diisobutyl 4′-aminobenzalmalonate)-s-triazine,
    2,4,6-Tris(dineopentyl 4′-aminobenzalmalonate)-s-triazine,
    2,4-Bis(dineopentyl 4′-aminobenzalmalonate)-6-(n-butyl 4′-aminobenzoate)-s-triazine,
    2,4-Bis(n-butyl 4′-aminobenzoate)-6-[(3-{1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-disiloxanylpropyl)amino]-s-triazine,
    the symmetrical triazine screening agents described in patent U.S. Pat. No. 6,225,467, patent application WO 2004/085 412 (see compounds 6 and 9) or the document Symmetrical Triazine Derivatives IP.COM Journal, IP.COM INC West Henrietta, N.Y., US (20 Sep. 2004), especially 2,4,6-tris(biphenyl)-1,3,5-triazines (in particular 2,4,6-tris(biphenyl-4-yl-1,3,5-triazine) and 2,4,6-tris(terphenyl)-1,3,5-triazine which is also mentioned in Beiersdorf patent applications WO 06/035 000, WO 06/034 982, WO 06/034 991, WO 06/035 007, WO 2006/034 992 and WO 2006/034 985,
  • Anthranilic Derivatives:
  • Menthyl anthranilate sold under the trade name Neo Heliopan MA by Symrise,
  • Imidazoline Derivatives:
  • Ethylhexyldimethoxybenzylidenedioxoimidazoline propionate,
  • Benzalmalonate Derivatives:
  • Dineopentyl 4′-methoxybenzalmalonate
    Polyorganosiloxane containing benzalmalonate functions, for instance Polysilicone-15, sold under the trade name Parsol SLX by Hoffmann LaRoche,
  • 4,4-Diarylbutadiene Derivatives:
  • 1,1-Dicarboxy(2,2′-dimethylpropyl)-4,4-diphenyl-butadiene,
  • Benzoxazole Derivatives:
  • 2,4-bis[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino]-6-(2-ethylhexyl)imino-1,3,5-triazine, sold under the name of Uvasorb K2A by Sigma 3V,
    and mixtures thereof.
  • The preferential additional organic screening agents are chosen from:
  • Ethylhexyl methoxycinnamate,
  • Homosalate,
  • Ethylhexyl salicylate,
  • Octocrylene,
  • Phenylbenzimidazolesulfonic acid,
  • Benzophenone-3, Benzophenone-4, Benzophenone-5,
  • n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)-benzoate,
    1,1′-(1,4-Piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]methanone,
  • 4-Methylbenzylidenecamphor,
  • Terephthalylidenedicamphorsulfonic acid,
    Disodium phenyldibenzimidazoletetrasulfonate,
    Ethylhexyl triazone,
  • Bis(ethylhexyloxyphenol)methoxyphenyltriazine, Diethylhexylbutamidotriazone,
  • 2,4,6-Tris(biphenyl-4-yl)-1,3,5-triazine,
    2,4,6-Tris(dineopentyl 4′-aminobenzalmalonate)-s-triazine,
    2,4,6-Tris(diisobutyl 4′-aminobenzalmalonate)-s-triazine,
    2,4-Bis(dineopentyl 4′-aminobenzalmalonate)-6-(n-butyl 4′-aminobenzoate)-s-triazine,
    2,4-Bis(n-butyl 4′-aminobenzoate)-6-[(3-{1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-disiloxanylpropyl)amino]-s-triazine,
  • Methylenebis(benzotriazolyl)tetramethylbutylphenol,
  • Drometrizole trisiloxane,
  • Polysilicone-15,
  • Dineopentyl 4′-methoxybenzalmalonate
    1,1-Dicarboxy(2,2′-dimethylpropyl)-4,4-diphenyl-butadiene,
    2,4-Bis[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino]-6-(2-ethylhexyl)imino-1,3,5-triazine,
    and mixtures thereof.
  • The additional mineral screening agents are chosen from coated or uncoated metal oxide pigments, for instance pigments of titanium oxide (amorphous or crystallized in rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide or cerium oxide, which are all UV-photoprotective agents that are well known per se.
  • The pigments may be coated or uncoated.
  • The coated pigments are pigments that have undergone one or more surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53-64, such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminium salts of fatty acids, metal alkoxides (of titanium or of aluminium), polyethylene, silicones, proteins (collagen, elastin), alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate.
  • As is known, silicones are organosilicon polymers or oligomers of linear or cyclic, branched or crosslinked structure, of variable molecular weight, obtained by polymerization and/or polycondensation of suitably functionalized silanes, and consist essentially of a repetition of main units in which the silicon atoms are linked together via oxygen atoms (siloxane bond), optionally substituted hydrocarbon-based radicals being directly attached via a carbon atom to the said silicon atoms.
  • The term “silicones” also includes the silanes required for their preparation, in particular alkyl silanes.
  • The silicones used for coating the nanopigments that are suitable for the present invention are preferably chosen from the group containing alkyl silanes, polydialkylsiloxanes and polyalkylhydrogenosiloxanes. Even more preferentially, the silicones are chosen from the group containing octyltrimethylsilane, polydimethylsiloxanes and polymethylhydrogenosiloxanes.
  • Needless to say, before being treated with silicones, the metal oxide pigments may have been treated with other surface agents, in particular with cerium oxide, alumina, silica, aluminium compounds or silicon compounds, or mixtures thereof.
  • The coated pigments are, for example, titanium oxides that have been coated: with silica, such as the product Sunveil from the company Ikeda and the product Eusolex T-AVO from the company Merck,
  • with silica and iron oxide, such as the product Sunveil F from the company Ikeda,
    with silica and alumina, such as the products Microtitanium Dioxide MT 500 SA and Microtitanium Dioxide MT 100 SA from the company Tayca, Tioveil from the company Tioxide and Mirasun TiW 60 from the company Rhodia,
    with alumina, such as the products Tipaque TTO-55 (B) and Tipaque TTO-55 (A) from the company Ishihara and UVT 14/4 from the company Kemira,
    with alumina and aluminium stearate, such as the product Microtitanium Dioxide MT 100 TV, MT 100 TX, MT 100 Z and MT-01 from the company Tayca, and the products Solaveil CT-10 W, Solaveil CT 100 and Solaveil CT 200 from the company Uniqema,
    with silica, alumina and alginic acid, such as the product MT-100 AQ from the company Tayca,
    with alumina and aluminium laurate, such as the product Microtitanium Dioxide MT 100 S from the company Tayca,
    with iron oxide and iron stearate, such as the product Microtitanium Dioxide MT 100 F from the company Tayca,
    with zinc oxide and zinc stearate, such as the product BR351 from the company Tayca,
    with silica and alumina and treated with a silicone, such as the products Microtitanium Dioxide MT 600 SAS, Microtitanium Dioxide MT 500 SAS or Microtitanium Dioxide MT 100 SAS from the company Tayca,
    with silica, alumina and aluminium stearate and treated with a silicone, such as the product STT-30-DS from the company Titan Kogyo,
    with silica and treated with a silicone, such as the product UV-Titan X 195 from the company Kemira, or the product SMT-100 WRS from the company Tayca,
    with alumina and treated with a silicone, such as the products Tipaque TTO-55 (S) from the company Ishihara or UV Titan M 262 from the company Kemira, with triethanolamine, such as the product STT-65-S from the company Titan Kogyo,
    with stearic acid, such as the product Tipaque TTO-55 (C) from the company Ishihara,
    with sodium hexametaphosphate, such as the product Microtitanium Dioxide MT 150 W from the company Tayca.
  • Other titanium oxide pigments treated with a silicone are, for example, TiO2 treated with octyltrimethylsilane, such as the product sold under the trade name T 805 by the company Degussa Silicas, TiO2 treated with a polydimethylsiloxane, such as the product sold under the trade name 70250 Cardre UF TiO2SI3 by the company Cardre, anatase/rutile TiO2 treated with a polydimethylhydrogenosiloxane, such as the product sold under the trade name Microtitanium Dioxide USP Grade Hydrophobic by the company Color Techniques.
  • The uncoated titanium oxide pigments are sold, for example, by the company Tayca under the trade names Microtitanium Dioxide MT 500 B or Microtitanium Dioxide MT 600 B, by the company Degussa under the name P 25, by the company Wacker under the name Transparent titanium oxide PW, by the company Miyoshi Kasei under the name UFTR, by the company Tomen under the name ITS and by the company Tioxide under the name Tioveil AQ.
  • The uncoated zinc oxide pigments are, for example:
      • those sold under the name Z-Cote by the company Sunsmart;
      • those sold under the name Nanox by the company Elementis;
      • those sold under the name Nanogard WCD 2025 by the company Nanophase Technologies.
  • The coated zinc oxide pigments are, for example:
      • those sold under the name Z-Cote HP1 by the company Sunsmart (dimethicone-coated ZnO);
      • those sold under the name Zinc Oxide CS-5 by the company Toshibi (ZnO coated with polymethylhydrogenosiloxane);
      • those sold under the name Nanogard Zinc Oxide FN by the company Nanophase Technologies (as a 40% dispersion in Finsolv TN, C12-C15 alkyl benzoate);
      • those sold under the name Daitopersion ZN-30 and Daitopersion ZN-50 by the company Daito (dispersions in cyclopolymethylsiloxane/oxyethylenated polydimethylsiloxane, containing 30% or 50% of nanozinc oxides coated with silica and polymethylhydrogenosiloxane);
      • those sold under the name NFD Ultrafine ZnO by the company Daikin (ZnO coated with perfluoroalkyl phosphate and copolymer based on perfluoroalkylethyl as a dispersion in cyclopentasiloxane);
      • those sold under the name SPD-Z1 by the company Shin-Etsu (ZnO coated with silicone-grafted acrylic polymer, dispersed in cyclodimethylsiloxane);
      • those sold under the name Escalol Z100 by the company ISP (alumina-treated ZnO dispersed in an ethylhexyl methoxycinnamate/PVP-hexadecene/methicone copolymer mixture);
      • those sold under the name Fuji ZnO-SMS-10 by the company Fuji Pigment (ZnO coated with silica and polymethylsilsesquioxane);
      • those sold under the name Nanox Gel TN by the company Elementis (ZnO dispersed at a concentration of 55% in C12-C15 alkyl benzoate with hydroxystearic acid polycondensate).
  • The uncoated cerium oxide pigments are sold, for example, under the name Colloidal Cerium Oxide by the company Rhône-Poulenc.
  • The uncoated iron oxide nanopigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2002 (FE 45B), Nanogard Iron FE 45 BL AQ, Nanogard FE 45R AQ and Nanogard WCD 2006 (FE 45R) or by the company Mitsubishi under the name TY-220,
  • The coated iron oxide pigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2008 (FE 45B FN), Nanogard WCD 2009 (FE 45B 556), Nanogard FE 45 BL 345 and Nanogard FE 45 BL or by the company BASF under the name Transparent Iron Oxide.
  • Mention may also be made of mixtures of metal oxides, especially of titanium dioxide and of cerium dioxide, including the silica-coated equal-weight mixture of titanium dioxide and of cerium dioxide, sold by the company Ikeda under the name Sunveil A, and also the alumina, silica and silicone-coated mixture of titanium dioxide and of zinc dioxide, such as the product M 261 sold by the company Kemira, or the alumina, silica and glycerol-coated mixture of titanium dioxide and of zinc dioxide, such as the product M 211 sold by the company Kemira.
  • The additional UV-screening agents are generally present in the compositions according to the invention in proportions ranging from 0.01% to 20% by weight relative to the total weight of the composition, and preferably ranging from 0.1% to 10% by weight relative to the total weight of the composition.
  • The compositions in accordance with the present invention may also comprise standard cosmetic adjuvants chosen especially from oils, waxes, organic solvents, ionic or nonionic, hydrophilic or lipophilic thickeners, softeners, humectants, opacifiers, stabilizers, emollients, silicones, antifoams, fragrances, preserving agents, anionic, cationic, nonionic, zwitterionic or amphoteric surfactants, active agents, fillers, polymers, propellants, acidifying or basifying agents or any other ingredient usually used in cosmetics and/or dermatology.
  • Oils that may be mentioned include mineral oils (paraffin); plant oils (sweet almond oil, macadamia oil, blackcurrant seed oil or jojoba oil); synthetic oils, for instance perhydrosqualene, fatty alcohols, fatty amides (for instance isopropyl lauroyl sarcosinate sold under the name Eldew SL-205 by the company Ajinomoto), fatty acids or fatty esters, for instance the C12-C15 alkyl benzoate sold under the trade name Finsolv TN or Witconol TN by the company Witco, 2-ethylphenyl benzoate, for instance the commercial product sold under the name X-Tend 226® by the company ISP, octyl palmitate, isopropyl lanolate and triglycerides, including capric/caprylic acid triglycerides, and dicaprylyl carbonate sold under the name Cetiol CC by the company Cognis, oxyethylenated or oxypropylenated fatty esters and ethers; silicone oils (cyclomethicone and polydimethylsiloxanes, or PDMS) or fluoro oils, polyalkylenes, and trialkyl trimellitates such as tridecyl trimellitate.
  • Examples of waxy compounds that may be mentioned include carnauba wax, beeswax, hydrogenated castor oil, polyethylene waxes and polymethylene waxes, for instance the product sold under the name Cirebelle 303 by the company Sasol.
  • Among the organic solvents that may be mentioned are lower alcohols and polyols. These polyols may be chosen from glycols and glycol ethers, for instance ethylene glycol, propylene glycol, butylene glycol, dipropylene glycol or diethylene glycol.
  • Hydrophilic thickeners that may be mentioned include carboxyvinyl polymers, such as Carbopols (Carbomers) and the Pemulens (acrylate/C10-C30-alkyl acrylate copolymer); polyacrylamides, for instance the crosslinked copolymers sold under the names Sepigel 305 (CTFA name: polyacrylamide/C13-14 isoparaffin/Laureth 7) or Simulgel 600 (CTFA name: acrylamide/sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80) by the company SEPPIC; 2-acrylamido-2-methylpropanesulfonic acid polymers and copolymers, optionally crosslinked and/or neutralized, for instance poly(2-acrylamido-2-methylpropanesulfonic acid) sold by the company Hoechst under the trade name Hostacerin AMPS (CTFA name: ammonium polyacryloyldimethyl taurate or Simulgel 800 sold by the company SEPPIC (CTFA name: sodium polyacryolyldimethyltaurate/polysorbate 80/sorbitan oleate); copolymers of 2-acrylamido-2-methylpropanesulfonic acid and of hydroxyethyl acrylate, for instance Simulgel NS and Sepinov EMT 10 sold by the company SEPPIC; cellulose derivatives such as hydroxyethylcellulose; polysaccharides and especially gums such as xanthan gum; water-soluble or water-dispersible silicone derivatives, for instance acrylic silicones, polyether silicones and cationic silicones, and mixtures thereof.
  • Lipophilic thickeners that may be mentioned include synthetic polymers, such as the poly(C10-C30 alkyl acrylates) sold under the names Intelimer IPA 13-1 and Intelimer IPA 13-6 by Landec, or modified clays, such as hectorite and its derivatives, for instance the products sold under the name Bentone.
  • Needless to say, a person skilled in the art will take care to select the optional additional compound(s) mentioned above and/or the amounts thereof such that the advantageous properties intrinsically associated with the compositions in accordance with the invention are not, or are not substantially, adversely affected by the envisaged addition(s), especially the improvement in the photostability of the dibenzoylmethane derivative.
  • The compositions according to the invention may be prepared according to the techniques that are well known to those skilled in the art. They may in particular be in the form of a simple or complex emulsion (O/W, W/O, O/W/O or W/O/W) such as a cream, a milk or a cream-gel; in the form of an aqueous gel; in the form of a lotion. They may optionally be packaged as an aerosol and may be in the form of a mousse or a spray.
  • The compositions according to the invention are preferably in the form of an oil-in-water or water-in-oil emulsion.
  • The emulsification processes that may be used are of paddle or impeller, rotor-stator and high-pressure homogenizer (HPH) type.
  • It is also possible, via HPH (between 50 and 800 bar), to obtain stable dispersions with drop sizes that may be as small as 100 nm.
  • The emulsions generally contain at least one emulsifying surfactant chosen from amphoteric, anionic, cationic and nonionic emulsifying surfactants, which are used alone or as a mixture. The emulsifiers are appropriately chosen according to the emulsion to be obtained (W/O or O/W).
  • As emulsifying surfactants that may be used for the preparation of the W/O emulsions, examples that may be mentioned include sorbitan, glycerol or sugar alkyl esters or ethers; silicone surfactants, for instance dimethicone copolyols, such as the mixture of cyclomethicone and of dimethicone copolyol, sold under the name DC 5225 C by the company Dow Corning, and alkyldimethicone copolyols such as laurylmethicone copolyol sold under the name Dow Corning 5200 Formulation Aid by the company Dow Corning; cetyl-dimethicone copolyol, such as the product sold under the name Abil EM 90R by the company Goldschmidt, and the mixture of cetyldimethicone copolyol, of polyglyceryl isostearate (4 mol) and of hexyl laurate, sold under the name Abil WE O9 by the company Goldschmidt. One or more co-emulsifiers may also be added thereto, which may be chosen advantageously from the group comprising polyol alkyl esters.
  • Polyol alkyl esters that may especially be mentioned include polyethylene glycol esters, for instance PEG-30 dipolyhydroxystearate, such as the product sold under the name Arlacel P135 by the company ICI.
  • Glycerol and/or sorbitan esters that may especially be mentioned include, for example, polyglyceryl isostearate, such as the product sold under the name Isolan GI 34 by the company Goldschmidt, sorbitan isostearate, such as the product sold under the name Arlacel 987 by the company ICI, sorbitan glyceryl isostearate, such as the product sold under the name Arlacel 986 by the company ICI, and mixtures thereof.
  • For the O/W emulsions, examples of emulsifiers that may be mentioned include nonionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) fatty acid esters of glycerol; oxyalkylenated fatty acid esters of sorbitan; oxyalkyl-enated (oxyethylenated and/or oxypropylenated) fatty acid esters, for instance the mixture PEG-100 stearate/glyceryl stearate sold, for example, by the company ICI under the name Arlacel 165; oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alkyl ethers; sugar esters, for instance sucrose stearate; fatty alkyl ethers of sugars, especially polyalkylglucosides (APG) such as decylglucoside and laurylglucoside sold, for example, by the company Henkel under the respective names Plantaren 2000 and Plantaren 1200, cetostearyl glucoside optionally as a mixture with cetostearyl alcohol, sold, for example, under the name Montanov 68 by the company SEPPIC, under the name Tegocare CG90 by the company Goldschmidt and under the name Emulgade KE3302 by the company Henkel, and also arachidyl glucoside, for example in the form of a mixture of arachidyl alcohol, behenyl alcohol and arachidyl glucoside, sold under the name Montanov 202 by the company SEPPIC. According to a specific embodiment of the invention, the mixture of the alkyl polyglucoside as defined above with the corresponding fatty alcohol can be in the form of a self-emulsifying composition, for example as disclosed in the document WO-A-92/06778.
  • When it is an emulsion, the aqueous phase of this emulsion may comprise a nonionic vesicular dispersion prepared according to known processes (Bangham, Standish and Watkins, J. Mol. Biol. 13, 238 (1965), FR 2 315 991 and FR 2 416 008).
  • The compositions according to the invention find their application in a large number of treatments, especially cosmetic treatments, of the skin, the lips and the hair, including the scalp, especially for protecting and/or caring for the skin, the lips and/or the hair, and/or for making up the skin and/or the lips.
  • Another subject of the present invention consists of the use of the compositions according to the invention as defined above for the manufacture of cosmetic products for treating the skin, the lips, the nails, the hair, the eyelashes, the eyebrows and/or the scalp, especially care products, antisun products and makeup products.
  • The cosmetic compositions according to the invention may be used, for example, as makeup products.
  • The cosmetic compositions according to the invention may be used, for example, as care products and/or antisun protection products for the face and/or the body, of liquid to semi-liquid consistency, such as milks, more or less rich creams, cream-gels and pastes. They may optionally be packaged as an aerosol and may be in the form of a mousse or a spray.
  • The compositions according to the invention in the form of vaporizable fluid lotions in accordance with the invention are applied to the skin or the hair in the form of fine particles by means of pressurization devices. The devices in accordance with the invention are well known to those skilled in the art and comprise non-aerosol pumps or “atomizers”, aerosol containers comprising a propellant and also aerosol pumps using compressed air as propellant. These devices are described in patents U.S. Pat. No. 4,077,441 and U.S. Pat. No. 4,850,517 (which form an integral part of the content of the description).
  • The compositions conditioned in aerosol form in accordance with the invention generally contain conventional propellants, for instance hydrofluoro compounds, dichlorodifluoromethane, difluoroethane, dimethyl ether, isobutane, n-butane, propane or trichlorofluoromethane. They are preferably present in amounts ranging from 15% to 50% by weight relative to the total weight of the composition.
  • The compositions according to the invention may also comprise additional cosmetic or dermatological active agents.
  • Mention may be made, among active agents, of:
      • vitamins (A, C, E, K, PP, and the like) and their derivatives or precursors, alone or as mixtures;
      • anti-ageing agents;
      • antioxidants;
      • free-radical scavengers;
      • antiglycation agents;
      • calmatives;
      • NO-synthase inhibitors;
      • agents for stimulating the synthesis of dermal or epidermal macromolecules and/or for preventing their degradation;
      • agents for stimulating fibroblast proliferation;
      • agents for stimulating keratinocyte proliferation;
      • dermorelaxants;
      • tensioning agents;
      • matting agents;
      • keratolytic agents;
      • desquamating agents;
      • moisturizers, for instance polyols such as glycerol, butylene glycol or propylene glycol;
      • antiinflammatory agents;
      • agents that act on the energy metabolism of cells;
      • insect repellents;
      • substance P or substance CRGP antagonists;
      • hair-loss counteractants and/or hair restorers;
      • antiwrinkle agents;
      • agents for modifying skin pigmentation;
      • astringents;
      • seboregulators and antiseborrhoeic agents.
  • Needless to say, a person skilled in the art will take care to select the optional additional compound(s) and/or the amounts thereof such that the advantageous properties intrinsically associated with the compositions in accordance with the invention are not, or are not substantially, adversely affected by the envisaged addition(s).
  • A person skilled in the art will select the said active agent(s) as a function of the effect desired on the skin, the hair, the eyelashes, the eyebrows and the nails.
  • The composition may also comprise at least one ingredient such as fillers with a soft-focus effect or agents for promoting the natural coloration of the skin, intended for complementing the biological effects of these active agents or for providing an immediate visual anti-ageing effect.
  • Other Additional Ingredients
  • The composition may also comprise at least one additional ingredient intended to provide an immediate visual effect. Mention may be made especially of agents that promotes the naturally pinkish coloration of the skin.
  • As agents that promote the naturally pinkish coloration of the skin, examples that may be mentioned include self-tanning agents, for instance an agent which, when applied to the skin, especially to the face, makes it possible to obtain a tanning effect more or less similar in appearance to that which may result from prolonged exposure to sunlight (natural tanning) or under a UV lamp.
  • Examples of self-tanning agents that may especially be mentioned include:
  • dihydroxyacetone (DHA),
    erythrulose, and
    the combination of a catalytic system formed from:
    manganese and/or zinc oxide salts, and
    alkali metal and/or alkaline-earth metal hydrogen carbonates.
  • The self-tanning agents are generally chosen from monocarbonyl or polycarbonyl compounds, for instance isatin, alloxan, ninhydrin, glyceraldehyde, mesotartaric aldehyde, glutaraldehyde, erythrulose, pyrazoline-4,5-dione derivatives as described in patent application FR 2 466 492 and WO 97/35842, dihydroxyacetone (DHA) and 4,4-dihydroxypyrazolin-5-one derivatives as described in patent application EP 903 342. DHA will preferably be used.
  • The DHA may be used in free and/or encapsulated form, for example in lipid vesicles such as liposomes, especially described in patent application WO 97/25970.
  • In general, the self-tanning agent is present in an amount ranging from 0.01% to 20% by weight and preferably in an amount of between 0.1% and 10% of the total weight of the composition.
  • Other dyes that allow modification of the colour produced by the self-tanning agent may also be used.
  • These dyes may be chosen from synthetic or natural direct dyes.
  • These dyes may be chosen, for example, from red or orange dyes of the fluorane type such as those described in patent application FR 2 840 806. Mention may be made, for example, of the following dyes:
      • tetrabromofluoresceine or eosin known under the CTFA name: CI 45380 or Red 21
      • phloxin B known under the CTFA name: CI 45410 or Red 27
      • diiodofluoresceine known under the CTFA name: CI 45425 or Orange 10;
      • dibromofluoresceine known under the CTFA name: CI 45370 or Orange 5;
      • the sodium salt of tetrabromofluoresceine known under the CTFA name: CI 45380 (Na salt) or Red 22;
      • the sodium salt of phloxin B known under the CTFA name: CI 45410 (Na salt) or Red 28;
      • the sodium salt of diiodofluoresceine known under the CTFA name: CI 45425 (Na salt) or Orange 11;
      • erythrosine known under the CTFA name: CI 45430 or Acid Red 51.
      • phloxin known under the CTFA name: CI 45405 or Acid Red 98.
  • These dyes may also be chosen from anthraquinones, caramel, carmine, carbon black, azulene blues, methoxalene, trioxalene, guajazulene, chamuzulene, rose Bengal, eosin 10B, cyanosin and daphinin.
  • These dyes may also be chosen from indole derivatives, for instance the monohydroxyindoles as described in patent FR 2 651 126 (i.e.: 4-, 5-, 6- or 7-hydroxyindole) or the dihydroxyindoles as described in patent EP-B-0 425 324 (i.e.: 5,6-dihydroxyindole, 2-methyl-5,6-dihydroxyindole, 3-methyl-5,6-dihydroxyindole or 2,3-dimethyl-5,6-dihydroxyindole).
  • EXAMPLES OF SYNTHESIS Example 1 Preparation of methyl (2Z,4E)-5-[bis(2-hydroxyethyl)amino]-2-(methylsulfonyl)penta-2,4-dienoate
  • Figure US20160058682A1-20160303-C00029
  • First step: Preparation of methyl (2Z,4E)-5-[acetyl(phenyl)amino]-2-(methylsulfonyl)penta-2,4-dienoate
  • 3-Anilinoacrolein aniline (2 g, 9×10−3 mol) and methylmethanesulfonyl acetate (1.37 ml, 9×10−3 mol) are heated at 105° C. in 5 ml of acetic anhydride for 2 hours 30 minutes. After cooling, the acetic anhydride is evaporated off under vacuum. The brown solid obtained is taken up in 40 ml of methanol and brought to reflux. After cooling, the solid obtained is filtered off, rinsed with cold methanol and dried. 1.6 g of a yellow powder (yield: 55%) of methyl (2Z,4E)-5-[acetyl(phenyl)amino]-2-(methylsulfonyl)penta-2,4-dienoate are recovered and are used in the following step without further processing.
  • Second step: Preparation of the compound of Example 1
  • A solution of the preceding product (2.3 g, 7.1×10−3 mol) and of diethanolamine (10.33 g, 6.23×10−3 mol) in 5.5 ml of acetonitrile is refluxed for 1 hour 15 minutes. After cooling, the acetonitrile is evaporated off under vacuum. The brown oil obtained is chromatographed on a column of silica (gradient of eluents: CH2Cl2/MeOH 100:0 to 90:10). 0.36 g (yield: 26%) of clean fractions of the derivative of Example 1 is thus obtained in the form of a pale yellow powder:
  • m. p: 73-76° C.

  • UV (Ethanol): λmax=367 nm, E 1%=2140
  • Example 2 Preparation of bis(4-hydroxybutyl)[(2E)-3-(dimethylamino)prop-2-en-1-ylidene]propanedioate
  • Figure US20160058682A1-20160303-C00030
  • First step: Preparation of bis[4-(benzyloxy)butyl]propanedioate
  • A heterogeneous mixture of 4-benzyloxy-1-butanol (9.5 g, 52.8×10−3 mol) and of malonic acid (2.5 ml, 24×10−3 mol) is brought to 50° C. with stirring. The catalyst concentrated H2SO4 (131 μL) is added, and the resulting mixture is left at 40° C. for 1 hour. After cooling, the grey residue is taken up in dichloromethane. The organic phase is washed with water (abundant foam). After evaporating off the solvent, the residue obtained is chromatographed on a column of silica to remove the starting alcohol (eluent: 90/10 heptane/EtOAc). 7.5 g (yield: 74%) of clean fractions of bis[4-(benzyloxy)butyl]propanedioate are recovered in the form of a pale yellow oil and are used in the following step without further processing.
  • Second step: Preparation of bis(4-hydroxybutyl) propanedioate
  • The preceding product (7.5 g, 0.0175 mol) dissolved in 350 ml of ethanol was subjected to continuous reductive hydrogenation (H-cube: 70 mm cartridge of 10% Pd on C; Full H2; 1 ml/min; 40° C.). After distilling off the ethanol under vacuum, 4.31 g (yield: 99%) of bis(4-hydroxybutyl) propanedioate are obtained in the form of a colourless oil and are used in the following step without further processing.
  • Third step: Preparation of the compound of Example 2
  • The preceding product (4.31 g, 0.0173 mol) and the catalysts n-octylamine (86 μL, 0.03 eq.) and acetic acid (199 μL, 0.2 eq.) in 20 ml of toluene are brought to reflux in a reactor inertized with nitrogen and on which is mounted Dean-Stark apparatus. N,N-Dimethylacrolein (1.74 ml, 0.0173 mol) dissolved in 10 ml of toluene is added dropwise to the reaction mixture. After boiling the reaction mixture for 3 hours 30 minutes, the same amounts of catalyst are added and refluxing is continued for 21 hours. After cooling, the solvent is evaporated off under vacuum and the brown oil obtained is chromatographed on a column of silica (gradient of eluents: isopropyl ether/acetone from 30:70 to 70:30). 703 mg (yield: 12%) of the derivative of Example 2 are thus obtained in the form of an orange-coloured oil:

  • UV (Ethanol): λmax=374 nm, E 1%=1600
  • Example 3 Preparation of 2-{[(2E,4E)-2-cyano-5-(diethylamino)penta-2,4-dienoyl]oxy}ethanesulfonate sodium salt
  • Figure US20160058682A1-20160303-C00031
  • First step: Preparation of sodium 2-{[(2E,4E)-2-cyano-5-(diethylamino)penta-2,4-dienoyl]oxy}ethanesulfonate
  • Thionyl chloride (15 ml) is reacted, with stirring, with cyanoacetic acid (2 g, 0.024 mol) and maintained at 40° C. for 2 hours. 50 ml of toluene are added and the mixture is concentrated under vacuum until a residual volume of 10 ml is obtained. The sodium salt of isethionic acid (3.48 g, 0.024 mol) is added thereto and the mixture is maintained at the reflux point of the toluene. The heterogeneous mixture is refluxed for 20 hours. After cooling, the reaction mixture is filtered. The solid is taken up in water and the aqueous phase is washed with ethyl acetate. The aqueous phase is brought to neutral pH with 2N sodium hydroxide. 1.6 g of a beige-coloured powder containing about 30% by mass of salts are recovered. The sodium salt of 2-{[(2E,4E)-2-cyano-5-(diethylamino)penta-2,4-dienoyl]oxy}ethanesulfonic acid is thus obtained, and is used in the following step without further processing.
  • Second step: Preparation of the compound of Example 3
  • The preceding product (1 g, 0.0032 mol) and the catalysts diethylamine (34 μL, 0.1 eq.) and acetic acid (19 μL, 0.1 eq.) in 5 ml of toluene are brought to reflux in a reactor inertized with nitrogen and on which is mounted Dean-Stark apparatus. N,N-Diethylacrolein (0.41 ml, 0.0032 mol) is added dropwise to the reaction mixture. After boiling the reaction mixture for 3 hours 30 minutes, the same amounts of catalyst are added and refluxing is continued for 21 hours. After cooling, the reaction mixture is filtered and the solid obtained is washed with diisopropyl ether. After chromatography on a reverse-phase column, 212 mg (yield: 22%) of the derivative of Example 3 are obtained in the form of a beige-coloured solid:

  • UV (H2O): λmax=370 nm, E 1%=1200
  • III/Formulation Examples Compositions A and B were Prepared
  • Ingredients Ex. A Ex. B
    EDTA 0.1 0.1
    Monopotassium monocetyl 1 1
    phosphate
    Deionized water qs 100 qs 100
    Triethanolamine 0.3 0.3
    Preserving agents 1.2 1.2
    C12-C15 alkyl benzoate 20 20
    Preserving agents 0.25 0.25
    Stearic acid 1.5 1.5
    Glyceryl 1 1
    mono/distearate/polyethylene
    glycol stearate (100 EO)
    mixture
    Cetyl alcohol 0.5 0.5
    Cetearyl alcohol and 2 2
    cetearyl glucoside
    Dimethicone (350 cSt) 0.5 0.5
    Triethanolamine 0.45 0.45
    Drometrizole trisiloxane 2 2
    Avobenzone (Parsol 1789) 2 2
    Merocyanin of formula (y) 1.5 0
    Merocyanin of formula (ac) 0 1.5
    2,4,6-tris[p-(2′-ethylhexyl-1′- 2 2
    oxycarbonyl)anilino]-1,3,5-
    triazine
    Isohexadecane 1 1
    Copolymer of acrylic acid 0.2 0.2
    and of C10-C30 alkyl
    methacrylate
    Xanthan 0.2 0.2
    Cyclopentadimethylsiloxane 5 5

Claims (10)

1. A process for improving the chemical stability towards UV radiation of at least one dibenzoylmethane derivative, which comprises combining the said dibenzoylmethane derivative is combined with an effective amount of at least one hydrophilic or water-soluble merocyanin UV-screening agent selected from the group formed by:
(1) those corresponding to one of the formulae (I) and (II) and also the salts thereof and the E,E-, E,Z- or Z,Z-geometrical isomer forms thereof below:
Figure US20160058682A1-20160303-C00032
in which:
R1 and R2, which may be identical or different, represent H; a linear or branched C1-C22 alkyl radical optionally containing from 1 to 3 oxygen atoms; a C3-C8 cycloalkyl radical, which is unsubstituted or substituted with C1-C4 alkyl radicals; the said radicals R1 and R2 optionally containing an alkylsulfonate radical in its acid or salified form or one or two hydroxyl radicals;
R1 and R2 may form, together with the nitrogen, a ring containing the group —(CH2)m—, which is uninterrupted or interrupted with one or more —O—, —S— or —NH—,
R1 may form, with the carbon alpha to the nitrogen, a ring containing the group —(CH2)m—, which is uninterrupted or interrupted with one or more —O—, —S— or —NH—,
R3 represents a carboxyl, —COOR5, —CONHR5, —COR5, —CONR5R1, SO2R5 or —CN group,
R4 represents a carboxyl, —COOR6, —CONHR6, —COR6, —CONR6R2 or SO2R6 group,
R5 and R6, which may be identical or different, represent a linear or branched C1-C22 alkyl radical optionally containing from 1 to 3 oxygen atoms; a C3-C8 cycloalkyl radical, which is unsubstituted or substituted with C1-C4 alkyl radicals; the said radicals R5 and R6 optionally containing an alkylsulfonate radical in its acid or salified form or one or two hydroxyl radicals,
Z represents the group —(CH2)l—, which is uninterrupted or interrupted with —O—, —S— or —NR7—, and/or unsubstituted or substituted with one or two C1-C6 alkyl radicals,
R7 is a C1-C5 alkyl radical optionally containing an alkylsulfonate radical in its acid or salified form or one or two hydroxyl radicals,
n is 1-2; —m is 1-7; —l is 1-4;
with at least one or two of the radicals R1, R2, R5, R6 and R7 containing
either an alkylsulfonate radical in its acid or salified form
or one or two hydroxyl radicals;
with the proviso that:
(i) when n=2, one of the radicals R1, R5 or R6 is an alkyl diradical or R1 and R2 together with two nitrogen atoms form a cyclic divalent radical —(CH2)m—;
(ii) R1 and R2 are not simultaneously a hydrogen atom;
(iii) when R3 is —CN, then at least one of the radicals R1, R2 or R6 must contain an alkylsulfonate group in its acid or salified form;
(2) the merocyanin compounds selected from the group formed by the following molecules, and also salts thereof and the E,E-, E,Z- or Z,Z-geometrical isomer forms thereof:
Figure US20160058682A1-20160303-C00033
Figure US20160058682A1-20160303-C00034
Figure US20160058682A1-20160303-C00035
Figure US20160058682A1-20160303-C00036
2. The process according to claim 1, in which the compounds of formula (I) are chosen from those for which the following conditions are satisfied:
R1 denotes hydrogen; a linear or branched C1-C8 alkyl radical optionally containing from 1 to 3 oxygen atoms,
R2 denotes a linear or branched C1-C8 alkyl radical optionally containing from 1 to 3 oxygen atoms or a C5-C6 cycloalkyl radical,
R3 denotes a group —COOR5, —CN or —CONHR5,
R4 denotes a group —COOR6, —CONHR6 or —SO2R6,
R5 denotes a linear or branched C1-C12 alkyl radical optionally containing from 1 to 3 oxygen atoms,
n is equal to 1 or 2;
with at least one or two of the radicals R1, R2, R5, R6 containing
either an alkylsulfonate radical in its acid or salified form
or one or two hydroxyl radicals.
3. The process according to claim 2, in which the compounds of formula (I) containing at least one alkylsulfonate group are chosen from those having the following formulae, and also the E,E, Z,Z, E,Z isomer forms thereof:
Figure US20160058682A1-20160303-C00037
Figure US20160058682A1-20160303-C00038
4. The process according to claim 2, in which the compounds of formula (I) containing hydroxyl groups are chosen from those having the following formulae:
Figure US20160058682A1-20160303-C00039
5. The process according to claim 1, in which the compounds of formula (II) are chosen from those for which the following conditions are satisfied:
R1 denotes hydrogen; a linear or branched C1-C10 alkyl radical optionally containing from 1 to 3 oxygen atoms,
R2 denotes a linear or branched C1-C10 alkyl radical optionally containing from 1 to 3 oxygen atoms; a C5-C6 cycloalkyl,
R3 denotes a group —COOR5 or CN,
R4 denotes a group —COOR6 or —SO2R6,
R5 denotes a linear or branched C1-C12 alkyl radical optionally containing from 1 to 3 oxygen atoms,
Z is —(CH2)3— which may or may not be substituted with two groups CH3,
n is equal to 1 or 2;
with at least one or two of the radicals R1, R2, R5, R6 and R7 containing
either an alkylsulfonate radical in its acid or salified form
or one or two hydroxyl radicals.
6. The process according to claim 5, in which the compounds of formula (II) are chosen from those having the following formulae, and also the E,E, Z,Z, E,Z isomer forms thereof:
Figure US20160058682A1-20160303-C00040
7. The process according to claim 1, in which the hydrophilic or water-soluble merocyanin UV screening agent(s) are chosen from the following compounds, and also the salts or the E,E, Z,Z, E,Z isomer forms thereof:
Figure US20160058682A1-20160303-C00041
Figure US20160058682A1-20160303-C00042
8. The process according to claim 1, in which the dibenzoylmethane derivative is 4-(tert-butyl)-4′-methoxydibenzoylmethane, or Butyl Methoxy Dibenzoylmethane or Avobenzone, having the following formula:
Figure US20160058682A1-20160303-C00043
9. A merocyanin compound with one or two alkylsulfonate radicals selected from the group consisting of the following compounds, and also salts thereof or E,E-, E,Z- or Z,Z-isomer forms thereof:
Figure US20160058682A1-20160303-C00044
Figure US20160058682A1-20160303-C00045
10. A merocyanin compounds selected from the group consisting of the following compounds, and also the salts thereof or E,E-, E,Z- or Z,Z-isomer forms thereof:
Figure US20160058682A1-20160303-C00046
Figure US20160058682A1-20160303-C00047
Figure US20160058682A1-20160303-C00048
Figure US20160058682A1-20160303-C00049
US14/845,342 2010-03-15 2015-09-04 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent Abandoned US20160058682A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/845,342 US20160058682A1 (en) 2010-03-15 2015-09-04 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
FR1051823A FR2957250B1 (en) 2010-03-15 2010-03-15 COMPOSITION CONTAINING DIBENZOYLMETHANE FILTER AND HYDROPHILIC OR WATER SOLUBLE MEROCYANINE UV FILTER; METHOD FOR PHOTOSTABILIZING THE DIBENZOYLMETHANE FILTER
FR1051823 2010-03-15
US28273310P 2010-03-24 2010-03-24
FR1058690 2010-10-22
FR1058690 2010-10-22
FR1059756 2010-11-25
FR1059756A FR2967900B1 (en) 2010-11-25 2010-11-25 COMPOSITION CONTAINING A DIBENZOYLMETHANE FILTER AND A HYDROPHILIC OR WATER-SOLUBLE MEROCYANINE UV FILTER; METHOD FOR PHOTOSTABILIZATION OF THE DIBENZOYLMETHANE FILTER
PCT/EP2011/053376 WO2011113718A1 (en) 2010-03-15 2011-03-07 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent
US201213634194A 2012-11-16 2012-11-16
US14/845,342 US20160058682A1 (en) 2010-03-15 2015-09-04 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/634,194 Division US9162976B2 (en) 2010-03-15 2011-03-07 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent
PCT/EP2011/053376 Division WO2011113718A1 (en) 2010-03-15 2011-03-07 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Publications (1)

Publication Number Publication Date
US20160058682A1 true US20160058682A1 (en) 2016-03-03

Family

ID=44262973

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/634,194 Active 2031-03-10 US9162976B2 (en) 2010-03-15 2011-03-07 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent
US14/845,342 Abandoned US20160058682A1 (en) 2010-03-15 2015-09-04 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/634,194 Active 2031-03-10 US9162976B2 (en) 2010-03-15 2011-03-07 Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Country Status (6)

Country Link
US (2) US9162976B2 (en)
EP (1) EP2547313A1 (en)
JP (1) JP2013522259A (en)
CN (1) CN102883704A (en)
BR (1) BR112012023232B1 (en)
WO (1) WO2011113718A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000460B2 (en) 2013-01-21 2021-05-11 L'oreal Cosmetic or dermatological composition comprising a merocyanine, an oily phase and a C1—C4 monoalkanol

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2734499T3 (en) 2011-07-21 2021-11-08 Oreal MEROCYANINE DERIVATIVES
EP2734499B1 (en) * 2011-07-21 2020-06-24 Basf Se Merocyanine derivatives
WO2013010590A1 (en) * 2011-07-21 2013-01-24 L'oreal Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities
FR2983716B1 (en) * 2011-12-12 2014-08-22 Oreal OIL-IN-SOLAR WATER EMULSION COMPRISING A HYDROPHOBIC POLYMER OF AT LEAST ONE VINYL MONOMER, A MIXTURE OF NON-IONIC OIL / WATER EMULSIFYING SURFACTANTS AND ANIONIC
FR3001143B1 (en) * 2013-01-21 2015-07-31 Oreal USE OF A REINFORCED SOLAR PROTECTIVE COMPOSITION IN LIGHT UVA PROTECTION TO PROTECT FROM HERPES PUSH INDUCED BY SOLAR EXPOSURE.
FR3001129B1 (en) * 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND A LIPOPHILIC UV BENZOTRIAZOLE FILTER
FR3001141B1 (en) * 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE, A TRIAZINE UVB FILTER AND AN ADDITIONAL ORGANIC UVA FILTER
FR3001133B1 (en) * 2013-01-21 2015-03-20 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE PARTICULATE AMIDE COMPOUND
BR112015017287B1 (en) * 2013-01-21 2020-03-10 L'oreal Cosmetic composition, non-therapeutic cosmetic processes and uses of a composition
FR3001136B1 (en) 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL EMULSION COMPRISING A MEROCYANINE AND AN EMULSIFIER SYSTEM CONTAINING AN AMPHIPHILIC POLYMER COMPRISING AT LEAST ONE ACRYLAMIDO 2-METHYLPROPANE SULFONIC ACIDIC PATTERN
FR3001137B1 (en) 2013-01-21 2015-02-27 Oreal COSMETIC OR DERMATOLOGICAL WATER-IN-OIL EMULSION COMPRISING A MEROCYANINE AND AT LEAST ONE EMULSIFYING POLYMER OF THE ESTER TYPE OF FATTY ACID AND GLYCOL POLYOXYALKYLENE
CN105307631B (en) 2013-01-21 2018-09-18 莱雅公司 Include the cosmetics or dermatological compositions of the UVA- smoke agents for shielding and/or the organic UVA- smoke agents for shielding of hydrophily of merocyanine and the 2- dihydroxy benaophenonel types of amino substitution
FR3001142B1 (en) * 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A HYDROPHILIC ORGANIC UVA FILTER AND AT LEAST ONE MEROCYANINE
FR3001128B1 (en) 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL EMULSION COMPRISING A MEROCYANINE AND AN EMULSIFYING SYSTEM CONTAINING AN ALKALINE METAL SALT OF ESTER OF PHOSPHORIC ACID AND FATTY ALCOHOL
ES2660222T3 (en) * 2013-01-21 2018-03-21 L'oréal Cosmetic or dermatological composition comprising a merocyanine and an insoluble organic UV protection agent and / or an insoluble inorganic UV protection agent
FR3001135B1 (en) * 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN INSOLUBLE INORGANIC UV FILTER
FR3001131B1 (en) 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL EMULSION COMPRISING A MEROCYANINE AND AN EMULSIFYING SYSTEM COMPRISING A GEMINE SURFACTANT.
EP2945605B1 (en) * 2013-01-21 2018-08-29 L'Oréal Cosmetic or dermatological composition comprising a merocyanine, an organic uvb-screening agent and an additional organic uva-screening agent
FR3001130B1 (en) * 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN INSOLUBLE ORGANIC UV FILTER
FR3001138B1 (en) * 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL ANHYDROUS COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE
US20170304658A1 (en) 2014-08-28 2017-10-26 L'oreal Gel/gel composition comprising a uv-screening agent
WO2016083404A1 (en) 2014-11-24 2016-06-02 L'oreal Cosmetic composition comprising a synthetic phyllosilicate and a polyol and/or a uv filter
FR3037243B1 (en) 2015-06-11 2018-11-16 L'oreal COMPOSITION COMPRISING UV FILTER, ANIONIC CROSSLINKABLE HYDROPHILIC POLYMER, SURFACTANT HAVING HLB LESS THAN OR EQUAL TO 5 AND SILICONE COPOLYMER
EP3334401B1 (en) 2015-06-19 2021-05-12 L'Oréal Sunscreen composition containing high levels of liposoluble uv filters
US10485745B2 (en) 2016-04-29 2019-11-26 L'oreal UV-A/UV-B sunscreen composition
FR3060355B1 (en) 2016-12-21 2020-01-24 L'oreal WATER-IN-OIL EMULSION CONTAINING BAICALIN, XANTHIC BASE, VITAMIN B3 AND MULTIVALENT METAL CATION SALT
FR3060361B1 (en) 2016-12-21 2018-12-07 L'oreal WATER-IN-OIL EMULSION COMPRISING A PARTICULAR EMULSIFYING SYSTEM, A LIPOPHILIC CLAY, AN ELASTOMERIC ORGANOPOLYSILOXANE POWDER COATED WITH A SILICONE RESIN
FR3060997B1 (en) 2016-12-23 2019-05-31 L'oreal COMPOSITION COMPRISING BAICALIN
FR3073402B1 (en) 2017-11-15 2020-05-15 L'oreal COMPOSITION COMPRISING BAICALIN AND / OR A DERIVATIVE THEREOF AND A PARTICULAR ACRYLIC POLYMER
FR3073400A1 (en) 2017-11-15 2019-05-17 L'oreal COSMETIC EMULSION CONTAINING A GEMINE SURFACTANT AND A LIPOPHILIC POLYMER
US10813875B2 (en) 2018-04-23 2020-10-27 L'oreal Memory shape sunscreen composition
AU2019303885A1 (en) * 2018-07-17 2021-03-11 Evonik Operations Gmbh CH-acidic methacrylic esters for the preparation of aqueous polymer dispersions
MX2021000530A (en) 2018-07-17 2021-06-08 Evonik Operations Gmbh Method for preparing c-h acidic (meth)acrylates.
FR3090329B1 (en) 2018-12-21 2020-12-04 Oreal Composition comprising a UV filter, an anionic crosslinked hydrophilic polymer, a surfactant having an HLB less than or equal to 5 and a non-volatile alkane
CN109796382A (en) * 2019-02-27 2019-05-24 江苏南大光电材料股份有限公司 The salty photo-acid generator of long flexible chain, preparation method and photoetching compositions
CN110420125A (en) * 2019-08-26 2019-11-08 屈威翰 A kind of compound resorcinol liposome and preparation method thereof
FR3103705B1 (en) 2019-11-29 2021-12-17 Oreal A composition comprising a UV filter, a block polymer containing a phosphonic acid group and a hydrocarbon oil
FR3103704B1 (en) 2019-11-29 2022-07-08 Oreal Composition comprising a UV filter, an ethylenic polymer with a phosphonic acid group and a hydrocarbon oil
FR3104975B1 (en) 2019-12-20 2021-12-17 Oreal Retinol-based composition
FR3104976B1 (en) 2019-12-20 2021-12-24 Oreal Composition based on retinol
FR3111075B1 (en) 2020-06-08 2022-12-16 Oreal Composition based on retinol
FR3111074B1 (en) 2020-06-08 2022-07-01 Oreal Composition based on retinol
FR3115991B1 (en) 2020-11-06 2023-11-03 Oreal Solid anhydrous composition comprising a lipophilic organic UV filter, a hydrocarbon oil, and at least 10% of a high melting point wax
FR3142344A1 (en) 2022-11-30 2024-05-31 L'oreal Retinol-based composition

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2463264A (en) 1942-12-23 1949-03-01 Ciba Ltd Derivatives of cyclic amidines and process of making same
US4045229A (en) 1974-09-17 1977-08-30 Eastman Kodak Company Novel UV absorbing compounds and photographic elements containing UV absorbing compounds
FR2315991A1 (en) 1975-06-30 1977-01-28 Oreal METHOD OF MANUFACTURING AQUEOUS DISPERSIONS OF LIPID SPHERULES AND CORRESPONDING NEW COMPOSITIONS
DE2544180C2 (en) 1975-10-03 1984-02-23 Merck Patent Gmbh, 6100 Darmstadt Light protection preparations for cosmetic purposes
US4077441A (en) 1976-08-16 1978-03-07 National Instrument Company Convertible filling machine
JPS53128333A (en) 1977-04-15 1978-11-09 Fuji Photo Film Co Ltd Prevention of influences of ultraviolet ray upon photosensitive material of silver halogenide
FR2416008A1 (en) 1978-02-02 1979-08-31 Oreal LIPOSOME LYOPHILISATES
NL190101C (en) 1978-11-13 1993-11-01 Givaudan & Cie Sa DIBENZOYL METHANE COMPOUND AND ANTI-LIGHT PROTECTIVE PREPARATION.
FR2466492A1 (en) 1979-10-03 1981-04-10 Elf Aquitaine Dyeing keratin substances, e.g. skin, nails, hair, fur - with compsns. contg. ketone or aldehyde dye and sulphoxy-aminoacid
JPS58178351A (en) * 1982-04-14 1983-10-19 Fuji Photo Film Co Ltd Photosensitive silver halide material
DE3302123A1 (en) 1983-01-22 1984-07-26 Haarmann & Reimer Gmbh NEW DIBENZOLE METHANE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE8322682U1 (en) 1983-08-05 1986-02-13 Siemens AG, 1000 Berlin und 8000 München Mechanical overload protection
NL8502651A (en) 1985-09-27 1987-04-16 Airspray Int Bv Atomizer for a container for a liquid to be atomized.
US5624663A (en) 1987-08-28 1997-04-29 L'oreal Photostable cosmetic filter composition cotaining a UV-A filter and a substituted dialkylbenzalmalonate, the use of substituted dialkylbenzalmalonates in cosmetics as broad-band solar filters and novel substituted dialkyl malonates
FR2651126B1 (en) 1989-08-29 1991-12-06 Oreal COMBINATION OF DIHYDROXYACETONE AND INDOLIC DERIVATIVES FOR GIVING SKIN A SIMILAR COLOR TO NATURAL TANNING AND METHOD FOR IMPLEMENTING SAME.
FR2668080B1 (en) 1990-10-17 1993-08-13 Seppic Sa SELF-EMULSIONABLE COMPOSITIONS BASED ON FATTY ALCOHOLS, THEIR PREPARATION PROCESS AND THEIR USE FOR MAKING EMULSIONS.
US5237071A (en) 1991-01-22 1993-08-17 Fairmount Chemical Company, Inc. Process for preparing 2,2'-methylene-bis(6-(2H-benzotriazol-2-yl)-4-hydrocarbyl phenols)
US5166355A (en) 1991-02-04 1992-11-24 Fairmount Chemical Co., Inc. Process for preparing substituted 2,2'-methylene-bis-[6-(2H-benzotriazol-2-yl)-4-hydrocarbyl-phenols]
FR2680683B1 (en) 1991-08-29 1993-11-12 Oreal COSMETIC FILTERING COMPOSITION CONTAINING A HYDROCARBON STRUCTURED FILTER POLYMER AND A FILTERED SILICONE.
ES2157268T5 (en) 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG COSMETIC AND DERMATOLOGICAL PREPARATIONS CONTAINING PHENYLENE-1,4-BISBENCIMIDAZOLSULFONIC ACIDS.
GB9515048D0 (en) 1995-07-22 1995-09-20 Ciba Geigy Ag Sunscreen compositions
DE19603018C2 (en) 1996-01-17 1998-02-26 Lancaster Group Gmbh Cosmetic self-tanning agent with light protection effect
FR2746391B1 (en) 1996-03-22 1998-04-17 Oreal COSMETIC COMPOSITIONS BASED ON PYRAZOLIN-4,5-DIONES, NEW PYRAZOLIN-4,5 DIONES, METHODS OF PREPARATION AND USES
IT1284525B1 (en) 1996-09-13 1998-05-21 3V Sigma Spa DERIVATIVES OF BENZOSSAZOLE USED AS STABILIZERS AGAINST UV RADIATION
DE19726184A1 (en) 1997-06-20 1998-12-24 Beiersdorf Ag Oil-in-water or multiple emulsion with high concentration of suspended UVB filter
GB9715751D0 (en) 1997-07-26 1997-10-01 Ciba Geigy Ag Formulations
DE19746654A1 (en) 1997-08-13 1999-02-18 Basf Ag Use of 4,4-di:aryl-butadiene derivatives as photostable UV filter compounds
DE19755649A1 (en) 1997-12-15 1999-06-17 Basf Ag Use of 4,4-diarylbutadienes as photostable UV filters in cosmetics
FR2768733B1 (en) 1997-09-19 1999-10-29 Oreal NOVEL 4,4-DIHYDROXYPYRAZOLIN-5-ONES COMPOUNDS; THEIR PREPARATION PROCESSES AND COSMETIC USES
DE19828463A1 (en) 1998-06-26 1999-12-30 Basf Ag 4,4-Diarylbutadienes as water-soluble, photostable UV filters for cosmetic and pharmaceutical preparations
DE19834565A1 (en) 1998-07-31 2000-02-03 Basf Ag Process for the preparation of 2-halogen nicotinic acid derivatives and new 2-chloronic nicotinic acid esters
DE19855649A1 (en) 1998-12-03 2000-06-08 Basf Ag Dimeric alpha-alkyl-styrene derivatives as photostable UV filters in cosmetic and pharmaceutical preparations
DE19857127A1 (en) 1998-12-11 2000-06-15 Basf Ag Oligomeric diarylbutadienes
IT1312374B1 (en) 1999-01-11 2002-04-15 3V Sigma Spa SOLAR FILTER ASSOCIATIONS AND COSMETIC COMPOSITIONS THAT CONTAIN IT
NO995093D0 (en) 1999-10-19 1999-10-19 Norsk Hydro As Method and apparatus for spot welding
US6225467B1 (en) 2000-01-21 2001-05-01 Xerox Corporation Electroluminescent (EL) devices
DE10012408A1 (en) 2000-03-15 2001-09-20 Basf Ag Use of sunscreen combinations which contain as essential constituent amino-substituted hydroxybenzophenones as photostable UV filters in cosmetic and pharmaceutical preparations
ITMI20012037A1 (en) 2001-10-02 2003-04-02 3V Sigma Spa SOLAR FILTER ASSOCIATIONS
DE10162844A1 (en) 2001-12-20 2003-07-03 Beiersdorf Ag Cosmetic and dermatological light protection formulations containing bis-resorcinyltriazine derivatives and benzoxazole derivatives
FR2840806B1 (en) 2002-06-13 2005-02-11 Oreal COLOR-SELF-TONING COMPOSITIONS COMPRISING AT LEAST ONE RED OR ORANGE COLOR, CHOSEN FROM FLUORANES OR THEIR ALKALI METAL SALTS
WO2004006878A1 (en) 2002-07-10 2004-01-22 Ciba Specialty Chemicals Holding Inc. Merocyanine derivatives for cosmetic use
WO2004075871A1 (en) 2003-02-26 2004-09-10 Fuji Photo Film B.V. Cosmetic uv-screen compositions and aminobutadiene-based uv-absorbing complexes therefor
KR101187002B1 (en) 2003-03-24 2012-09-28 시바 홀딩 인코포레이티드 Symmetrical Triazine derivatives
EP1701695B1 (en) 2003-12-17 2016-04-20 Basf Se Merocyanine derivatives for cosmetic use
GB2416351A (en) 2004-06-29 2006-01-25 Ciba Sc Holding Ag Use of myocyanine derivatives for the protection of human hair and skin from UV radiation
ATE429436T1 (en) 2004-09-20 2009-05-15 Oreal SILANE MEROCYANINE SULPHONE DERIVATIVES, PHOTOPROTECTION COMPOSITIONS THEREOF, USE THEREOF AS UV FILTER
DE102004047286B4 (en) 2004-09-27 2006-11-23 Beiersdorf Ag Cosmetic sunscreen preparation based on micropigments
DE102004047285A1 (en) 2004-09-27 2006-04-20 Beiersdorf Ag Cosmetic sunscreen emulsion containing organic micropigments
DE102004047283A1 (en) 2004-09-27 2006-04-13 Beiersdorf Ag O / W emulsions with inorganic UV photoprotective pigments
DE102004047288B4 (en) 2004-09-27 2006-11-30 Beiersdorf Ag Sunscreen emulsion with a high proportion of sunscreen filter pigments
DE102004047282A1 (en) 2004-09-27 2006-04-20 Beiersdorf Ag W / O emulsion with UV sunscreen filter pigments
DE102004047281A1 (en) 2004-09-27 2006-04-20 Beiersdorf Ag Sunscreen concentrate with organic micropigments
FR2886144B1 (en) * 2005-05-27 2007-06-29 Oreal METHOD FOR PHOTOSTABILIZING A DIBENZOYLMETHANE DERIVATIVE WITH A MEROCYANINE SULFONE DERIVATIVE; PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING THE SAME.
AU2006274968B2 (en) * 2005-07-29 2012-02-23 Basf Se Stabilization of body-care and household products against degradation by UV radiation using merocyanine derivatives
CN101277674B (en) * 2005-07-29 2013-01-16 西巴特殊化学制品控股公司 Stabilization of body-care and household products against degradation by UV radiation using merocyanine derivatives
GB2445635A (en) * 2006-10-13 2008-07-16 Ciba Sc Holding Ag Merocyanine derivatives useful as UV absorbers
JP5733895B2 (en) * 2007-01-25 2015-06-10 チバ ホールディング インコーポレーテッドCiba Holding Inc. Stabilization of UV-sensitive active ingredients
JP4879158B2 (en) 2007-12-27 2012-02-22 富士フイルム株式会社 Holographic recording compound, holographic recording composition, and holographic recording medium

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000460B2 (en) 2013-01-21 2021-05-11 L'oreal Cosmetic or dermatological composition comprising a merocyanine, an oily phase and a C1—C4 monoalkanol

Also Published As

Publication number Publication date
BR112012023232A2 (en) 2020-10-27
CN102883704A (en) 2013-01-16
US20130058990A1 (en) 2013-03-07
BR112012023232B1 (en) 2021-03-23
EP2547313A1 (en) 2013-01-23
WO2011113718A1 (en) 2011-09-22
JP2013522259A (en) 2013-06-13
US9162976B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
US9162976B2 (en) Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent
AU2012285709B2 (en) Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities
US8961941B2 (en) Composition comprising a dibenzoylmethane screening agent and a merocyanine dicyano or cyanoacetate derivative; method for the photostabilization of the dibenzoylmethane screening agent
US7364721B2 (en) Photostabilization of dibenzoylmethane UV-screening agents with arylalkyl benzoate compounds and photoprotective cosmetic compositions comprised thereof
US20140134120A1 (en) Photoprotective composition
US20060104924A1 (en) Photostable photoprotective compositions comprising dibenzoylmethane and arylalkyl benzoate compounds and a compound that accepts the excited triplet level energy of said dibenzoylmethane(s)
US20080019930A1 (en) Dibenzoylmethane sunscreens photostabilized with arylalkyl amide or ester compounds
US7368105B2 (en) Photostabilization of dibenzoylmethane UV-screening agents with arylalkyl benzoate/bis-resorcinyl triazine compounds and photoprotective compositions comprised thereof
US20170135933A1 (en) Photoprotective compositions comprising photosensitive 1,3,5-triazine compounds, dibenzoylmethane compounds and siliceous s-triazines substituted with two aminobenzoate or aminobenzamide groups
US20080317685A1 (en) Photoprotective cosmetic compositions comprising photostabilized dibenzoylmethane compounds and siloxane-containing arylalkyl benzoate amide compounds
US20070218022A1 (en) Photostable sunscreen compositions comprising cinnamic acid ester UV-B filters, dibenzoylmethane UV-A filters and s-triazine compounds
WO2007080053A2 (en) Cosmetic composition containing a dibenzoylmethane derivative and a phenol or bisphenol compound; process for photostabilization of the dibenzoylmethane derivative
WO2007080052A1 (en) Cosmectic composition containing a dibenzoylmethane derivative and a siloxane-containing phenol or bisphenol compound; process for photostabilization of the dibenzoylmethane derivative
EP1815884A2 (en) Compositions containing an UV-B filter of the cinnamic acid ester type, a UV-A filter of the dibenzoylmethane type and a derivative of s-triazine; process of photostabilisation
EP1815886A2 (en) Compositions containing a UV-A filter of the dibenzoylmethane type and a s-triazine derivative; process of photostabilisation
EP1649900B1 (en) Light screening composition comprising a derivative of dibenzoylmethane, a bis-resorcinyl triazine and a compound capable of accepting energy of the excited triplet state of dibenzoylmethane; process for photostabilisation
US20080008669A1 (en) Photostable sunscreen compositions comprising cinnamate ester UV-B filters and s-triazine compounds
US20110097365A1 (en) S-triazine derivatives containing at least two particular silane aminobenzoate or silane aminobenzamide groups; photoprotective cosmetic compositions containing these derivatives; uses of the said s-triazine derivatives
FR2902652A1 (en) Cosmetic composition comprises a dibenzoylmethane UV-A filter and an aromatic ester
US8999299B2 (en) Photoprotective cosmetic compositions comprising silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups and non-silicon-containing lipophilic triazine compound UV-screening agents
JP4713251B2 (en) Method for photoprotecting dibenzoylmethane derivatives using arylalkyl benzoate derivatives and bis-resorcinyltriazine compounds, and photoprotective compositions
US20070196294A1 (en) Photostable sunscreen compositions comprising dibenzoylmethane compound UV-A filters and s-triazine compounds
EP1911438A2 (en) Cosmetic composition containing a derivative of dibenzoylmethane and a arylalkyl amide or ester compound; method of photostabilising the derivative of dibenzoylmethane
FR2973233A1 (en) Cosmetic process, useful for filtering UV rays, comprises applying, on a surface of a keratinous material, preferably skin and/or hair, a cosmetic composition comprising betaine salicylate in a medium
FR2902650A1 (en) Cosmetic composition comprises a dibenzoylmethane UV-A filter and an aromatic amide

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION